Western Kenya Cancer Statistics
Western Kenya Cancer Statistics
Authors: ECR Group
1 Background
Eldoret Cancer Registry was established in 1999. It is located in the Faculty of Medical Sciences of Moi University, Department of Haematology and Blood Transfusion. The registry records details of all cancer patients diagnosed and treated in hospitals of Eldoret town, and aims to be population-based for the district of Uasin Gishu, in the Rift Valley Region of Kenya (pop. 2009: 894,179). As well as the Director (Dr N. Buziba), the registry has three registrars, Gladys Chesumbai , Jacqueline Gavana, and Jane Chepkosgei. Because of shortage of funds in the last 6 years, the staff work only part time basis on registry duties. Case-finding uses three types of source: hospital records departments, pathology and death
2 Datasource
The largest hospital is Moi Teaching and Referral Hospital which also acts as the Province General Hospital. Cases are identified from the disease index (completed by records staff in ICD-10) and details of cases abstracted from case records onto a registry form. The registrars also visits private hospitals (Eldoret, Elgon View, Medi-Heal Fertility Hospital, St. Lukes and Reale Hospital) and the Eldoret Hospice at regular intervals to identify cancer cases, although because of financial constraints, visits were widely spaced in recent years. There is only one public pathology lab. Serving the District (in Moi Teaching and Referral Hospital), with four pathologists and 2 private pathology labs. The registrar abstracts details of all cancer diagnoses (address is usually unavailable). Haematological malignancies are all diagnosed by the registry director and his junior- Dr. Lotodo (Department of Haematology and Blood Transfusion).
Death registration is virtually universal (home deaths should also be autopsied, but this is a rare event). The death certificate may not be issued for some weeks after death, however. Deaths at home are certified by the village chief, based on relatives’ assessments, and are of very questionable accuracy (often just “cancer”).
Cases are coded in the registry, and data entry and management is by CANREG-5. By January 2013, some 16,000 cases had been registered, about one half of which are in residents of Uasin Gishu district.
3 Study Population
Eldoret: Situated some 330 km northwest of Nairobi, Eldoret is the largest city and the administrative capital of Uasin Gishu County.
Moi’s Bridge: Located some 40 km north of Eldoret along Eldoret – Kitale road, Moi’s bridge is a small yet an important agricultural town.
Burnt Forest: Sited some 35 kilometers to Eldoret, Burnt Forest is the first major town as you approach Eldoret from Nairobi.
Turbo: Turbo is a small agricultural town located about 31 km west of Eldoret town along Eldoret -Webuye road.
Others: Outside the county
4 Objective
The main objective of this study/analysis is to assess the incidence and prevalence of different cancer types from 2000 to 2020
5 Results Overall | 2001 to 2020
5.1 Distribution of Cases by County
5.1.1 County Distribution Map
5.1.2 County Distribution Graph | Top 20 Counties
5.1.3 County Distribution Table
Table X: Name of table | ||||
label | variable | Sex | Total | |
Female | Male | |||
County | Baringo | 511 (51%) | 490 (49%) | 1001 (3%) |
Bomet | 291 (46%) | 336 (54%) | 627 (2%) | |
Bungoma | 1391 (56%) | 1110 (44%) | 2501 (6%) | |
Busia | 594 (51%) | 577 (49%) | 1171 (3%) | |
CENTRAL | 5 (56%) | 4 (44%) | 9 (0.02%) | |
COAST | 0 (0%) | 1 (100%) | 1 (0.003%) | |
EASTERN-NOS | 0 (0%) | 1 (100%) | 1 (0.003%) | |
Elgeyo-Marakwet | 629 (49%) | 645 (51%) | 1274 (3%) | |
Embu | 7 (70%) | 3 (30%) | 10 (0.03%) | |
FOREIGN | 10 (50%) | 10 (50%) | 20 (0.05%) | |
Garissa | 2 (50%) | 2 (50%) | 4 (0.01%) | |
Homa-Bay | 330 (52%) | 303 (48%) | 633 (2%) | |
Isiolo | 1 (25%) | 3 (75%) | 4 (0.01%) | |
Kajiado | 5 (33%) | 10 (67%) | 15 (0.04%) | |
Kakamega | 1238 (53%) | 1086 (47%) | 2324 (6%) | |
Kericho | 577 (49%) | 610 (51%) | 1187 (3%) | |
Kiambu | 26 (68%) | 12 (32%) | 38 (0.1%) | |
Kilifi | 6 (75%) | 2 (25%) | 8 (0.02%) | |
Kirinyaga | 3 (75%) | 1 (25%) | 4 (0.01%) | |
Kisii | 699 (51%) | 666 (49%) | 1365 (3%) | |
Kisumu | 516 (50%) | 507 (50%) | 1023 (3%) | |
Kitui | 8 (73%) | 3 (27%) | 11 (0.03%) | |
Kwale | 2 (67%) | 1 (33%) | 3 (0.008%) | |
Laikipia | 24 (52%) | 22 (48%) | 46 (0.1%) | |
Lamu | 3 (75%) | 1 (25%) | 4 (0.01%) | |
Machakos | 7 (58%) | 5 (42%) | 12 (0.03%) | |
Makueni | 3 (43%) | 4 (57%) | 7 (0.02%) | |
Mandera | 2 (50%) | 2 (50%) | 4 (0.01%) | |
Marsabit | 8 (62%) | 5 (38%) | 13 (0.03%) | |
Meru | 17 (65%) | 9 (35%) | 26 (0.07%) | |
Migori | 155 (49%) | 161 (51%) | 316 (1%) | |
Mombasa | 25 (71%) | 10 (29%) | 35 (0.09%) | |
Muranga | 6 (38%) | 10 (62%) | 16 (0.04%) | |
N.EASTERN | 1 (50%) | 1 (50%) | 2 (0.005%) | |
Nairobi | 36 (49%) | 37 (51%) | 73 (0.2%) | |
Nakuru | 462 (60%) | 305 (40%) | 767 (2%) | |
Nandi | 1257 (48%) | 1366 (52%) | 2623 (7%) | |
Narok | 137 (44%) | 175 (56%) | 312 (1%) | |
Nyandarua | 25 (52%) | 23 (48%) | 48 (0.1%) | |
Nyanza | 57 (37%) | 98 (63%) | 155 (0.4%) | |
Nyeri | 20 (71%) | 8 (29%) | 28 (0.07%) | |
Siaya | 250 (46%) | 289 (54%) | 539 (1%) | |
Taita-Taveta | 3 (60%) | 2 (40%) | 5 (0.01%) | |
Tharaka-Nithi | 0 (0%) | 1 (100%) | 1 (0.003%) | |
Trans-nzoia | 1002 (53%) | 878 (47%) | 1880 (5%) | |
Turkana | 114 (40%) | 174 (60%) | 288 (1%) | |
Uasin-Gishu | 5981 (53%) | 5395 (47%) | 11376 (29%) | |
Unknown | 3602 (55%) | 2896 (45%) | 6498 (16%) | |
Vihiga | 282 (55%) | 235 (45%) | 517 (1%) | |
Wajir | 3 (50%) | 3 (50%) | 6 (0.02%) | |
West Pokot | 321 (51%) | 306 (49%) | 627 (2%) | |
WESTERN | 53 (59%) | 37 (41%) | 90 (0.2%) | |
Total | 20707 (52%) | 18841 (48%) | 39548 (100%) | |
5.2 Distribution of Cases by Socio-Demographics
5.2.1 Age-groups (Age)
5.2.2 Gender
5.2.3 Gender + Age Graph
5.2.4 Gender + Age Table
Table X: Name of table | ||||
label | variable | Sex | Total | |
Female | Male | |||
Age Group | 0-4 | 578 (44%) | 747 (56%) | 1325 (3%) |
5-9 | 505 (39%) | 785 (61%) | 1290 (3%) | |
10-14 | 505 (40%) | 769 (60%) | 1274 (3%) | |
15-19 | 554 (44%) | 697 (56%) | 1251 (3%) | |
20-24 | 601 (54%) | 512 (46%) | 1113 (3%) | |
25-29 | 862 (57%) | 660 (43%) | 1522 (4%) | |
30-34 | 1461 (60%) | 983 (40%) | 2444 (6%) | |
35-39 | 1659 (62%) | 1026 (38%) | 2685 (7%) | |
40-44 | 2138 (64%) | 1209 (36%) | 3347 (9%) | |
45-49 | 1893 (60%) | 1283 (40%) | 3176 (8%) | |
50-54 | 1902 (59%) | 1344 (41%) | 3246 (8%) | |
55-59 | 1877 (56%) | 1503 (44%) | 3380 (9%) | |
60-64 | 1760 (51%) | 1690 (49%) | 3450 (9%) | |
65-69 | 1368 (47%) | 1569 (53%) | 2937 (8%) | |
70-74 | 1145 (43%) | 1500 (57%) | 2645 (7%) | |
> 75 | 1327 (40%) | 1954 (60%) | 3281 (8%) | |
Unknown | 389 (52%) | 355 (48%) | 744 (2%) | |
Total | 20524 (52%) | 18586 (48%) | 39110 (100%) | |
5.3 Trends / Incidences over Time
5.3.1 Trends by Gender
5.4 Distribution of Cancer Types
5.4.1 Most Common Cancer Types by Gender
5.4.1.1 All Gender
Table X: Frequency and Proportions of all Cancer Types | All Gender | |||||||||||||||||||
label | variable | Age Group | Total | ||||||||||||||||
0-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | > 75 | Unknown | |||
ICD10 Site | C00: LIP | 1 (4%) | 1 (4%) | 1 (4%) | 2 (8%) | 1 (4%) | 0 (0%) | 2 (8%) | 4 (16%) | 3 (12%) | 1 (4%) | 4 (16%) | 0 (0%) | 2 (8%) | 2 (8%) | 1 (4%) | 0 (0%) | 0 (0%) | 25 (0.06%) |
C01-C02: TONGUE | 0 (0%) | 1 (0.4%) | 0 (0%) | 2 (1%) | 1 (0.4%) | 13 (5%) | 7 (3%) | 10 (4%) | 21 (9%) | 41 (17%) | 15 (6%) | 30 (12%) | 29 (12%) | 20 (8%) | 28 (12%) | 16 (7%) | 7 (3%) | 241 (1%) | |
C03-C06: MOUTH | 4 (2%) | 0 (0%) | 3 (2%) | 2 (1%) | 4 (2%) | 5 (3%) | 5 (3%) | 11 (7%) | 11 (7%) | 14 (8%) | 13 (8%) | 21 (13%) | 20 (12%) | 15 (9%) | 17 (10%) | 18 (11%) | 4 (2%) | 167 (0.4%) | |
C07-C08: SALIVARY GLANDS | 7 (4%) | 2 (1%) | 2 (1%) | 5 (3%) | 5 (3%) | 5 (3%) | 11 (7%) | 8 (5%) | 18 (12%) | 6 (4%) | 11 (7%) | 16 (10%) | 12 (8%) | 12 (8%) | 12 (8%) | 22 (14%) | 2 (1%) | 156 (0.4%) | |
C09: TONSILS | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (8%) | 2 (17%) | 3 (25%) | 2 (17%) | 0 (0%) | 2 (17%) | 2 (17%) | 0 (0%) | 0 (0%) | 0 (0%) | 12 (0.03%) | |
C10: OROPHARYNX | 0 (0%) | 0 (0%) | 1 (2%) | 1 (2%) | 2 (3%) | 5 (8%) | 1 (2%) | 1 (2%) | 9 (15%) | 8 (14%) | 6 (10%) | 4 (7%) | 8 (14%) | 7 (12%) | 3 (5%) | 3 (5%) | 0 (0%) | 59 (0.2%) | |
C11: NASOPHARYNX | 3 (0.3%) | 10 (1%) | 66 (7%) | 101 (11%) | 87 (9%) | 53 (6%) | 63 (7%) | 58 (6%) | 83 (9%) | 91 (10%) | 81 (9%) | 63 (7%) | 70 (7%) | 46 (5%) | 21 (2%) | 24 (3%) | 15 (2%) | 935 (2%) | |
C12-C13: HYPOPHARYNX | 0 (0%) | 0 (0%) | 1 (1%) | 8 (9%) | 4 (5%) | 5 (6%) | 4 (5%) | 4 (5%) | 9 (11%) | 7 (8%) | 9 (11%) | 6 (7%) | 11 (13%) | 5 (6%) | 4 (5%) | 5 (6%) | 3 (4%) | 85 (0.2%) | |
C14: OTHER PHARYNX | 1 (1%) | 0 (0%) | 2 (3%) | 2 (3%) | 1 (1%) | 5 (7%) | 2 (3%) | 2 (3%) | 5 (7%) | 8 (12%) | 11 (16%) | 8 (12%) | 8 (12%) | 4 (6%) | 5 (7%) | 4 (6%) | 0 (0%) | 68 (0.2%) | |
C15: ESOPHAGUS | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 18 (1%) | 57 (2%) | 91 (3%) | 120 (4%) | 206 (6%) | 296 (9%) | 366 (11%) | 453 (14%) | 465 (14%) | 409 (12%) | 388 (12%) | 427 (13%) | 0 (0%) | 3296 (8%) | |
C16: STOMACH | 1 (0.09%) | 0 (0%) | 2 (0.2%) | 7 (1%) | 16 (1%) | 13 (1%) | 38 (3%) | 53 (5%) | 63 (5%) | 79 (7%) | 104 (9%) | 120 (10%) | 159 (14%) | 141 (12%) | 133 (11%) | 207 (18%) | 28 (2%) | 1164 (3%) | |
C17: SMALL INTESTINE | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (2%) | 3 (7%) | 1 (2%) | 6 (14%) | 4 (10%) | 7 (17%) | 4 (10%) | 6 (14%) | 6 (14%) | 1 (2%) | 3 (7%) | 0 (0%) | 42 (0.1%) | |
C18: COLON | 0 (0%) | 0 (0%) | 3 (0.4%) | 14 (2%) | 16 (2%) | 31 (4%) | 54 (7%) | 45 (5%) | 66 (8%) | 74 (9%) | 90 (11%) | 93 (11%) | 103 (13%) | 62 (8%) | 68 (8%) | 79 (10%) | 23 (3%) | 821 (2%) | |
C19-C20: HYPOPHARYNX | 0 (0%) | 0 (0%) | 0 (0%) | 12 (2%) | 13 (2%) | 23 (4%) | 43 (7%) | 50 (8%) | 71 (11%) | 55 (9%) | 70 (11%) | 65 (10%) | 67 (10%) | 71 (11%) | 43 (7%) | 51 (8%) | 7 (1%) | 641 (2%) | |
C21: ANUS | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) | 5 (4%) | 8 (6%) | 7 (5%) | 12 (9%) | 13 (10%) | 13 (10%) | 13 (10%) | 16 (12%) | 12 (9%) | 7 (5%) | 10 (8%) | 10 (8%) | 1 (1%) | 128 (0.3%) | |
C22: LIVER | 12 (1%) | 5 (0.4%) | 9 (1%) | 16 (1%) | 33 (3%) | 35 (3%) | 77 (7%) | 105 (9%) | 113 (10%) | 111 (10%) | 109 (9%) | 118 (10%) | 114 (10%) | 86 (7%) | 74 (6%) | 101 (9%) | 35 (3%) | 1153 (3%) | |
C23-C24: GALL BLADDER | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) | 3 (2%) | 5 (4%) | 7 (6%) | 10 (8%) | 16 (13%) | 19 (16%) | 13 (11%) | 17 (14%) | 17 (14%) | 11 (9%) | 3 (2%) | 122 (0.3%) | |
C25: PANCREAS | 1 (0.2%) | 0 (0%) | 1 (0.2%) | 1 (0.2%) | 4 (1%) | 3 (1%) | 16 (3%) | 18 (3%) | 37 (6%) | 49 (9%) | 50 (9%) | 65 (11%) | 78 (14%) | 78 (14%) | 80 (14%) | 83 (14%) | 11 (2%) | 575 (1%) | |
C26: GASTROINTESTINAL | 0 (0%) | 0 (0%) | 1 (3%) | 0 (0%) | 3 (9%) | 0 (0%) | 0 (0%) | 3 (9%) | 4 (12%) | 3 (9%) | 0 (0%) | 5 (15%) | 3 (9%) | 5 (15%) | 4 (12%) | 2 (6%) | 0 (0%) | 33 (0.08%) | |
C30-C31: SINUSES, NOSE, ETC | 3 (3%) | 1 (1%) | 2 (2%) | 5 (5%) | 7 (6%) | 7 (6%) | 6 (6%) | 7 (6%) | 13 (12%) | 9 (8%) | 9 (8%) | 7 (6%) | 13 (12%) | 8 (7%) | 4 (4%) | 3 (3%) | 4 (4%) | 108 (0.3%) | |
C32: LARYNX | 0 (0%) | 0 (0%) | 0 (0%) | 2 (1%) | 7 (3%) | 0 (0%) | 3 (1%) | 12 (5%) | 11 (4%) | 17 (7%) | 29 (11%) | 35 (14%) | 52 (20%) | 27 (10%) | 35 (14%) | 25 (10%) | 4 (2%) | 259 (1%) | |
C33-C34: TRACHEA, BRONCHUS, LUNG | 0 (0%) | 1 (0.2%) | 1 (0.2%) | 3 (1%) | 4 (1%) | 11 (2%) | 19 (3%) | 19 (3%) | 37 (6%) | 41 (7%) | 54 (9%) | 81 (14%) | 74 (13%) | 68 (12%) | 75 (13%) | 61 (11%) | 26 (5%) | 575 (1%) | |
C37-C38: THYMUS | 1 (2%) | 0 (0%) | 5 (9%) | 2 (4%) | 2 (4%) | 3 (5%) | 4 (7%) | 6 (11%) | 3 (5%) | 6 (11%) | 3 (5%) | 3 (5%) | 7 (12%) | 3 (5%) | 3 (5%) | 5 (9%) | 0 (0%) | 56 (0.1%) | |
C39: RESPIRATORY TRACT | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (25%) | 1 (25%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (25%) | 0 (0%) | 1 (25%) | 0 (0%) | 4 (0.01%) | |
C40-C41: BONES - LIMBS | 12 (2%) | 36 (6%) | 107 (17%) | 154 (24%) | 63 (10%) | 30 (5%) | 39 (6%) | 33 (5%) | 19 (3%) | 24 (4%) | 22 (3%) | 18 (3%) | 19 (3%) | 17 (3%) | 14 (2%) | 19 (3%) | 11 (2%) | 637 (2%) | |
C42: BLOOD, SPLEEN | 67 (7%) | 61 (7%) | 88 (10%) | 42 (5%) | 43 (5%) | 49 (5%) | 57 (6%) | 39 (4%) | 44 (5%) | 52 (6%) | 47 (5%) | 74 (8%) | 58 (6%) | 48 (5%) | 38 (4%) | 52 (6%) | 51 (6%) | 910 (2%) | |
C43: MELANOMA OF SKIN | 2 (1%) | 3 (1%) | 2 (1%) | 4 (2%) | 4 (2%) | 7 (3%) | 8 (3%) | 11 (4%) | 12 (5%) | 18 (7%) | 29 (11%) | 36 (14%) | 25 (10%) | 37 (15%) | 23 (9%) | 33 (13%) | 0 (0%) | 254 (1%) | |
C44: OTHER SKIN | 7 (1%) | 8 (1%) | 18 (2%) | 23 (2%) | 32 (3%) | 57 (6%) | 80 (8%) | 80 (8%) | 87 (9%) | 71 (7%) | 72 (8%) | 80 (8%) | 81 (9%) | 57 (6%) | 67 (7%) | 101 (11%) | 30 (3%) | 951 (2%) | |
C45: KAPOSISARCOMA | 23 (1%) | 41 (2%) | 39 (2%) | 54 (2%) | 99 (4%) | 288 (12%) | 513 (21%) | 436 (18%) | 356 (14%) | 228 (9%) | 152 (6%) | 90 (4%) | 61 (2%) | 34 (1%) | 38 (2%) | 27 (1%) | 0 (0%) | 2479 (6%) | |
C47-C49: CONNECTIVE & SOFT TISSUE | 113 (11%) | 72 (7%) | 82 (8%) | 93 (9%) | 70 (7%) | 54 (5%) | 71 (7%) | 66 (7%) | 53 (5%) | 63 (6%) | 44 (4%) | 56 (6%) | 56 (6%) | 39 (4%) | 28 (3%) | 26 (3%) | 23 (2%) | 1009 (3%) | |
C50: BREAST | 0 (0%) | 0 (0%) | 0 (0%) | 22 (1%) | 55 (2%) | 131 (4%) | 273 (8%) | 410 (12%) | 520 (15%) | 448 (13%) | 412 (12%) | 331 (9%) | 326 (9%) | 219 (6%) | 165 (5%) | 203 (6%) | 0 (0%) | 3515 (9%) | |
C51: VULVA | 0 (0%) | 0 (0%) | 2 (1%) | 0 (0%) | 3 (2%) | 7 (4%) | 20 (12%) | 18 (10%) | 30 (17%) | 13 (8%) | 13 (8%) | 19 (11%) | 14 (8%) | 12 (7%) | 8 (5%) | 8 (5%) | 5 (3%) | 172 (0.4%) | |
C52: VAGINA | 3 (7%) | 1 (2%) | 0 (0%) | 1 (2%) | 0 (0%) | 1 (2%) | 4 (9%) | 3 (7%) | 5 (12%) | 5 (12%) | 5 (12%) | 7 (16%) | 1 (2%) | 4 (9%) | 2 (5%) | 0 (0%) | 1 (2%) | 43 (0.1%) | |
C53: CERVIX UTERI | 0 (0%) | 0 (0%) | 0 (0%) | 10 (0.3%) | 26 (1%) | 115 (3%) | 257 (7%) | 402 (11%) | 582 (15%) | 514 (14%) | 477 (13%) | 434 (11%) | 373 (10%) | 238 (6%) | 188 (5%) | 174 (5%) | 0 (0%) | 3790 (10%) | |
C54: CORPUS UTERI | 0 (0%) | 0 (0%) | 1 (0.3%) | 2 (1%) | 1 (0.3%) | 4 (1%) | 10 (3%) | 7 (2%) | 25 (8%) | 18 (6%) | 36 (11%) | 51 (16%) | 59 (19%) | 39 (12%) | 28 (9%) | 24 (8%) | 10 (3%) | 315 (1%) | |
C55: UTERUS, NOS | 0 (0%) | 0 (0%) | 1 (1%) | 2 (1%) | 9 (6%) | 8 (6%) | 10 (7%) | 14 (10%) | 13 (9%) | 12 (8%) | 19 (13%) | 15 (10%) | 8 (6%) | 8 (6%) | 11 (8%) | 12 (8%) | 2 (1%) | 144 (0.4%) | |
C56: OVARY | 6 (1%) | 4 (1%) | 15 (2%) | 36 (5%) | 28 (4%) | 40 (5%) | 43 (6%) | 56 (7%) | 87 (12%) | 65 (9%) | 70 (9%) | 86 (11%) | 67 (9%) | 67 (9%) | 29 (4%) | 46 (6%) | 5 (1%) | 750 (2%) | |
C57: FEMALE GEN.- OTHER | 2 (18%) | 0 (0%) | 1 (9%) | 2 (18%) | 1 (9%) | 1 (9%) | 1 (9%) | 0 (0%) | 2 (18%) | 0 (0%) | 0 (0%) | 1 (9%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 11 (0.03%) | |
C58: PLACENTA | 0 (0%) | 0 (0%) | 0 (0%) | 3 (4%) | 15 (22%) | 14 (20%) | 19 (28%) | 3 (4%) | 11 (16%) | 2 (3%) | 1 (1%) | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 69 (0.2%) | |
C60: PENIS | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) | 1 (1%) | 8 (8%) | 11 (11%) | 12 (12%) | 14 (14%) | 12 (12%) | 10 (10%) | 5 (5%) | 8 (8%) | 9 (9%) | 6 (6%) | 1 (1%) | 98 (0.3%) | |
C61: PROSTATE | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (0.1%) | 2 (0.1%) | 4 (0.2%) | 4 (0.2%) | 5 (0.2%) | 19 (1%) | 46 (2%) | 132 (7%) | 280 (14%) | 384 (19%) | 466 (23%) | 681 (34%) | 0 (0%) | 2025 (5%) | |
C62: TESTIS | 3 (6%) | 3 (6%) | 0 (0%) | 6 (12%) | 5 (10%) | 3 (6%) | 7 (13%) | 1 (2%) | 4 (8%) | 4 (8%) | 1 (2%) | 6 (12%) | 2 (4%) | 2 (4%) | 0 (0%) | 4 (8%) | 1 (2%) | 52 (0.1%) | |
C63: MALE GEN.- OTHER | 0 (0%) | 1 (8%) | 0 (0%) | 0 (0%) | 1 (8%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (8%) | 0 (0%) | 4 (33%) | 0 (0%) | 1 (8%) | 1 (8%) | 1 (8%) | 1 (8%) | 1 (8%) | 12 (0.03%) | |
C64: KIDNEY | 272 (46%) | 123 (21%) | 20 (3%) | 8 (1%) | 4 (1%) | 8 (1%) | 8 (1%) | 11 (2%) | 24 (4%) | 14 (2%) | 16 (3%) | 27 (5%) | 13 (2%) | 25 (4%) | 5 (1%) | 12 (2%) | 6 (1%) | 596 (2%) | |
C65: RENAL PELVIS | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (40%) | 0 (0%) | 1 (20%) | 0 (0%) | 2 (40%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 5 (0.01%) | |
C67: BLADDER | 3 (1%) | 0 (0%) | 2 (1%) | 0 (0%) | 3 (1%) | 2 (1%) | 7 (3%) | 9 (3%) | 21 (8%) | 15 (6%) | 20 (8%) | 25 (10%) | 37 (14%) | 40 (15%) | 35 (13%) | 35 (13%) | 7 (3%) | 261 (1%) | |
C68: URETHRA, OTHER | 0 (0%) | 2 (12%) | 0 (0%) | 0 (0%) | 2 (12%) | 1 (6%) | 0 (0%) | 1 (6%) | 0 (0%) | 2 (12%) | 1 (6%) | 2 (12%) | 3 (19%) | 1 (6%) | 0 (0%) | 1 (6%) | 0 (0%) | 16 (0.04%) | |
C69: EYE | 206 (40%) | 51 (10%) | 13 (3%) | 6 (1%) | 7 (1%) | 16 (3%) | 33 (6%) | 33 (6%) | 43 (8%) | 27 (5%) | 20 (4%) | 7 (1%) | 13 (3%) | 12 (2%) | 9 (2%) | 6 (1%) | 8 (2%) | 510 (1%) | |
C70-C72: BRAIN, NERVOUS SYSTEM | 43 (8%) | 47 (9%) | 39 (7%) | 31 (6%) | 30 (6%) | 27 (5%) | 35 (6%) | 39 (7%) | 32 (6%) | 29 (5%) | 49 (9%) | 47 (9%) | 28 (5%) | 30 (6%) | 20 (4%) | 13 (2%) | 4 (1%) | 543 (1%) | |
C73: THYROID | 0 (0%) | 1 (0.3%) | 3 (1%) | 9 (2%) | 13 (3%) | 17 (4%) | 22 (6%) | 29 (7%) | 42 (11%) | 37 (9%) | 59 (15%) | 32 (8%) | 38 (10%) | 34 (9%) | 19 (5%) | 26 (7%) | 14 (4%) | 395 (1%) | |
C74: ADRENAL GLAND | 7 (21%) | 6 (18%) | 4 (12%) | 5 (15%) | 2 (6%) | 2 (6%) | 2 (6%) | 2 (6%) | 0 (0%) | 2 (6%) | 1 (3%) | 0 (0%) | 0 (0%) | 1 (3%) | 0 (0%) | 0 (0%) | 0 (0%) | 34 (0.09%) | |
C75: ENDOCRINE GLANDS | 0 (0%) | 1 (7%) | 0 (0%) | 0 (0%) | 1 (7%) | 1 (7%) | 2 (14%) | 2 (14%) | 1 (7%) | 1 (7%) | 0 (0%) | 0 (0%) | 1 (7%) | 2 (14%) | 2 (14%) | 0 (0%) | 0 (0%) | 14 (0.04%) | |
C76: ILL-DEFINED | 25 (7%) | 24 (7%) | 18 (5%) | 14 (4%) | 18 (5%) | 17 (5%) | 21 (6%) | 21 (6%) | 26 (7%) | 24 (7%) | 22 (6%) | 28 (8%) | 24 (7%) | 24 (7%) | 16 (5%) | 24 (7%) | 5 (1%) | 351 (1%) | |
C77: LYMPH NODES | 30 (7%) | 51 (12%) | 46 (11%) | 42 (10%) | 22 (5%) | 20 (5%) | 24 (6%) | 23 (6%) | 24 (6%) | 22 (5%) | 22 (5%) | 12 (3%) | 13 (3%) | 12 (3%) | 8 (2%) | 9 (2%) | 32 (8%) | 412 (1%) | |
C81-C85, C96: LYMPHOMA | 258 (10%) | 420 (16%) | 361 (14%) | 234 (9%) | 132 (5%) | 119 (5%) | 144 (6%) | 136 (5%) | 151 (6%) | 138 (5%) | 105 (4%) | 107 (4%) | 90 (3%) | 62 (2%) | 65 (3%) | 50 (2%) | 1 (0.04%) | 2573 (7%) | |
C88: MULTIPLE MYELOMA | 0 (0%) | 1 (25%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (25%) | 0 (0%) | 0 (0%) | 1 (25%) | 0 (0%) | 0 (0%) | 1 (25%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (0.01%) | |
C90-C95: LEUKAEMIA | 176 (6%) | 283 (9%) | 272 (9%) | 186 (6%) | 143 (5%) | 147 (5%) | 174 (6%) | 134 (4%) | 162 (5%) | 197 (7%) | 218 (7%) | 226 (8%) | 214 (7%) | 174 (6%) | 149 (5%) | 158 (5%) | 0 (0%) | 3013 (8%) | |
OTHER | 0 (0%) | 0 (0%) | 0 (0%) | 2 (10%) | 0 (0%) | 1 (5%) | 2 (10%) | 0 (0%) | 6 (29%) | 2 (10%) | 2 (10%) | 1 (5%) | 0 (0%) | 2 (10%) | 0 (0%) | 3 (14%) | 0 (0%) | 21 (0.05%) | |
UNKNOWN | 33 (1%) | 29 (1%) | 40 (2%) | 74 (3%) | 45 (2%) | 48 (2%) | 86 (4%) | 94 (4%) | 135 (6%) | 147 (6%) | 177 (7%) | 185 (8%) | 211 (9%) | 202 (8%) | 176 (7%) | 366 (15%) | 353 (15%) | 2401 (6%) | |
Total | 1325 (3%) | 1290 (3%) | 1274 (3%) | 1251 (3%) | 1113 (3%) | 1522 (4%) | 2444 (6%) | 2685 (7%) | 3347 (9%) | 3176 (8%) | 3246 (8%) | 3380 (9%) | 3450 (9%) | 2937 (8%) | 2645 (7%) | 3281 (8%) | 744 (2%) | 39110 (100%) | |
5.4.1.2 Female
Table X: Frequency and Proportions of all Cancer Types | Female | |||||||||||||||||||
label | variable | Age Group | Total | ||||||||||||||||
0-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | > 75 | Unknown | |||
ICD10 Site | C00: LIP | 1 (7%) | 0 (0%) | 1 (7%) | 2 (13%) | 0 (0%) | 0 (0%) | 2 (13%) | 2 (13%) | 1 (7%) | 1 (7%) | 3 (20%) | 0 (0%) | 1 (7%) | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 15 (0.07%) |
C01-C02: TONGUE | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) | 1 (1%) | 4 (5%) | 5 (6%) | 6 (7%) | 7 (9%) | 11 (14%) | 4 (5%) | 13 (16%) | 10 (12%) | 3 (4%) | 9 (11%) | 6 (7%) | 1 (1%) | 81 (0.4%) | |
C03-C06: MOUTH | 2 (2%) | 0 (0%) | 3 (3%) | 1 (1%) | 3 (3%) | 3 (3%) | 3 (3%) | 9 (10%) | 3 (3%) | 4 (5%) | 6 (7%) | 5 (6%) | 14 (16%) | 7 (8%) | 11 (13%) | 11 (13%) | 2 (2%) | 87 (0.4%) | |
C07-C08: SALIVARY GLANDS | 4 (5%) | 1 (1%) | 0 (0%) | 2 (3%) | 2 (3%) | 4 (5%) | 6 (8%) | 4 (5%) | 10 (14%) | 1 (1%) | 6 (8%) | 8 (11%) | 6 (8%) | 3 (4%) | 6 (8%) | 11 (15%) | 0 (0%) | 74 (0.4%) | |
C09: TONSILS | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (12%) | 2 (25%) | 1 (12%) | 2 (25%) | 0 (0%) | 1 (12%) | 1 (12%) | 0 (0%) | 0 (0%) | 0 (0%) | 8 (0.04%) | |
C10: OROPHARYNX | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (6%) | 1 (6%) | 0 (0%) | 0 (0%) | 5 (28%) | 3 (17%) | 0 (0%) | 0 (0%) | 3 (17%) | 3 (17%) | 1 (6%) | 1 (6%) | 0 (0%) | 18 (0.09%) | |
C11: NASOPHARYNX | 1 (0.3%) | 2 (1%) | 21 (7%) | 36 (11%) | 37 (12%) | 20 (6%) | 25 (8%) | 25 (8%) | 27 (9%) | 24 (8%) | 17 (5%) | 22 (7%) | 22 (7%) | 19 (6%) | 7 (2%) | 5 (2%) | 6 (2%) | 316 (2%) | |
C12-C13: HYPOPHARYNX | 0 (0%) | 0 (0%) | 1 (3%) | 3 (9%) | 0 (0%) | 1 (3%) | 4 (12%) | 4 (12%) | 5 (15%) | 5 (15%) | 3 (9%) | 2 (6%) | 2 (6%) | 1 (3%) | 1 (3%) | 0 (0%) | 1 (3%) | 33 (0.2%) | |
C14: OTHER PHARYNX | 0 (0%) | 0 (0%) | 1 (6%) | 1 (6%) | 0 (0%) | 4 (24%) | 1 (6%) | 0 (0%) | 1 (6%) | 2 (12%) | 1 (6%) | 0 (0%) | 2 (12%) | 0 (0%) | 1 (6%) | 3 (18%) | 0 (0%) | 17 (0.08%) | |
C15: ESOPHAGUS | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 9 (1%) | 23 (2%) | 44 (4%) | 38 (3%) | 79 (7%) | 91 (8%) | 112 (9%) | 150 (12%) | 165 (14%) | 176 (15%) | 164 (14%) | 162 (13%) | 0 (0%) | 1213 (6%) | |
C16: STOMACH | 1 (0.2%) | 0 (0%) | 0 (0%) | 1 (0.2%) | 5 (1%) | 8 (2%) | 16 (4%) | 22 (5%) | 28 (6%) | 37 (8%) | 43 (9%) | 39 (9%) | 60 (13%) | 52 (11%) | 50 (11%) | 79 (17%) | 12 (3%) | 453 (2%) | |
C17: SMALL INTESTINE | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (7%) | 2 (14%) | 0 (0%) | 5 (36%) | 0 (0%) | 1 (7%) | 1 (7%) | 3 (21%) | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 14 (0.07%) | |
C18: COLON | 0 (0%) | 0 (0%) | 2 (1%) | 6 (2%) | 10 (3%) | 14 (4%) | 26 (7%) | 19 (5%) | 38 (11%) | 31 (9%) | 40 (11%) | 31 (9%) | 37 (10%) | 31 (9%) | 23 (7%) | 38 (11%) | 7 (2%) | 353 (2%) | |
C19-C20: HYPOPHARYNX | 0 (0%) | 0 (0%) | 0 (0%) | 5 (2%) | 8 (3%) | 9 (3%) | 24 (8%) | 26 (9%) | 32 (11%) | 29 (10%) | 31 (11%) | 29 (10%) | 20 (7%) | 33 (12%) | 12 (4%) | 22 (8%) | 3 (1%) | 283 (1%) | |
C21: ANUS | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (5%) | 4 (6%) | 4 (6%) | 7 (11%) | 8 (12%) | 10 (15%) | 9 (14%) | 8 (12%) | 4 (6%) | 3 (5%) | 3 (5%) | 2 (3%) | 0 (0%) | 65 (0.3%) | |
C22: LIVER | 5 (1%) | 4 (1%) | 4 (1%) | 5 (1%) | 14 (3%) | 10 (2%) | 30 (7%) | 42 (9%) | 35 (8%) | 44 (10%) | 40 (9%) | 51 (12%) | 46 (10%) | 32 (7%) | 20 (5%) | 44 (10%) | 17 (4%) | 443 (2%) | |
C23-C24: GALL BLADDER | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) | 2 (2%) | 4 (5%) | 4 (5%) | 9 (10%) | 13 (15%) | 14 (16%) | 5 (6%) | 14 (16%) | 10 (12%) | 7 (8%) | 3 (3%) | 86 (0.4%) | |
C25: PANCREAS | 1 (0.4%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (1%) | 0 (0%) | 6 (2%) | 6 (2%) | 17 (6%) | 20 (7%) | 27 (10%) | 23 (8%) | 41 (15%) | 40 (15%) | 39 (14%) | 42 (15%) | 5 (2%) | 271 (1%) | |
C26: GASTROINTESTINAL | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (7%) | 0 (0%) | 0 (0%) | 1 (7%) | 2 (14%) | 1 (7%) | 0 (0%) | 2 (14%) | 2 (14%) | 2 (14%) | 1 (7%) | 2 (14%) | 0 (0%) | 14 (0.07%) | |
C30-C31: SINUSES, NOSE, ETC | 1 (2%) | 0 (0%) | 0 (0%) | 2 (5%) | 3 (7%) | 4 (10%) | 2 (5%) | 4 (10%) | 3 (7%) | 4 (10%) | 4 (10%) | 2 (5%) | 5 (12%) | 1 (2%) | 4 (10%) | 2 (5%) | 1 (2%) | 42 (0.2%) | |
C32: LARYNX | 0 (0%) | 0 (0%) | 0 (0%) | 1 (2%) | 0 (0%) | 0 (0%) | 1 (2%) | 4 (10%) | 4 (10%) | 1 (2%) | 4 (10%) | 6 (14%) | 8 (19%) | 4 (10%) | 6 (14%) | 3 (7%) | 0 (0%) | 42 (0.2%) | |
C33-C34: TRACHEA, BRONCHUS, LUNG | 0 (0%) | 1 (0.4%) | 0 (0%) | 1 (0.4%) | 2 (1%) | 4 (1%) | 11 (4%) | 9 (3%) | 16 (6%) | 22 (8%) | 25 (9%) | 41 (15%) | 31 (12%) | 31 (12%) | 32 (12%) | 30 (11%) | 12 (4%) | 268 (1%) | |
C37-C38: THYMUS | 1 (5%) | 0 (0%) | 4 (19%) | 0 (0%) | 1 (5%) | 1 (5%) | 3 (14%) | 1 (5%) | 2 (10%) | 2 (10%) | 1 (5%) | 1 (5%) | 3 (14%) | 0 (0%) | 0 (0%) | 1 (5%) | 0 (0%) | 21 (0.1%) | |
C39: RESPIRATORY TRACT | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (25%) | 1 (25%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (25%) | 0 (0%) | 1 (25%) | 0 (0%) | 4 (0.02%) | |
C40-C41: BONES - LIMBS | 4 (1%) | 15 (5%) | 52 (18%) | 65 (23%) | 25 (9%) | 9 (3%) | 20 (7%) | 14 (5%) | 11 (4%) | 15 (5%) | 7 (2%) | 9 (3%) | 7 (2%) | 11 (4%) | 6 (2%) | 12 (4%) | 6 (2%) | 288 (1%) | |
C42: BLOOD, SPLEEN | 33 (8%) | 27 (7%) | 28 (7%) | 15 (4%) | 22 (5%) | 24 (6%) | 25 (6%) | 20 (5%) | 16 (4%) | 30 (7%) | 28 (7%) | 36 (9%) | 33 (8%) | 17 (4%) | 11 (3%) | 21 (5%) | 26 (6%) | 412 (2%) | |
C43: MELANOMA OF SKIN | 1 (1%) | 1 (1%) | 0 (0%) | 3 (2%) | 2 (1%) | 5 (4%) | 5 (4%) | 5 (4%) | 4 (3%) | 9 (7%) | 16 (12%) | 20 (15%) | 14 (10%) | 21 (15%) | 16 (12%) | 15 (11%) | 0 (0%) | 137 (1%) | |
C44: OTHER SKIN | 4 (1%) | 5 (1%) | 11 (2%) | 12 (3%) | 17 (4%) | 23 (5%) | 33 (7%) | 37 (8%) | 48 (10%) | 26 (6%) | 29 (6%) | 48 (10%) | 42 (9%) | 26 (6%) | 38 (8%) | 54 (12%) | 13 (3%) | 466 (2%) | |
C45: KAPOSISARCOMA | 3 (0.3%) | 8 (1%) | 15 (2%) | 25 (3%) | 57 (6%) | 139 (16%) | 196 (22%) | 141 (16%) | 126 (14%) | 72 (8%) | 39 (4%) | 24 (3%) | 17 (2%) | 8 (1%) | 9 (1%) | 8 (1%) | 0 (0%) | 887 (4%) | |
C47-C49: CONNECTIVE & SOFT TISSUE | 59 (13%) | 36 (8%) | 37 (8%) | 40 (9%) | 30 (7%) | 29 (6%) | 26 (6%) | 26 (6%) | 26 (6%) | 24 (5%) | 25 (5%) | 24 (5%) | 25 (5%) | 17 (4%) | 15 (3%) | 12 (3%) | 10 (2%) | 461 (2%) | |
C50: BREAST | 0 (0%) | 0 (0%) | 0 (0%) | 22 (1%) | 54 (2%) | 128 (4%) | 272 (8%) | 393 (12%) | 504 (15%) | 426 (13%) | 392 (12%) | 314 (9%) | 291 (9%) | 193 (6%) | 144 (4%) | 179 (5%) | 0 (0%) | 3312 (16%) | |
C51: VULVA | 0 (0%) | 0 (0%) | 2 (1%) | 0 (0%) | 3 (2%) | 7 (4%) | 20 (12%) | 18 (10%) | 30 (17%) | 13 (8%) | 13 (8%) | 19 (11%) | 14 (8%) | 12 (7%) | 8 (5%) | 8 (5%) | 5 (3%) | 172 (1%) | |
C52: VAGINA | 3 (7%) | 1 (2%) | 0 (0%) | 1 (2%) | 0 (0%) | 1 (2%) | 4 (9%) | 3 (7%) | 5 (12%) | 5 (12%) | 5 (12%) | 7 (16%) | 1 (2%) | 4 (9%) | 2 (5%) | 0 (0%) | 1 (2%) | 43 (0.2%) | |
C53: CERVIX UTERI | 0 (0%) | 0 (0%) | 0 (0%) | 10 (0.3%) | 26 (1%) | 115 (3%) | 257 (7%) | 402 (11%) | 582 (15%) | 514 (14%) | 477 (13%) | 434 (11%) | 373 (10%) | 238 (6%) | 188 (5%) | 174 (5%) | 0 (0%) | 3790 (18%) | |
C54: CORPUS UTERI | 0 (0%) | 0 (0%) | 1 (0.3%) | 2 (1%) | 1 (0.3%) | 4 (1%) | 10 (3%) | 7 (2%) | 25 (8%) | 18 (6%) | 36 (11%) | 51 (16%) | 59 (19%) | 39 (12%) | 28 (9%) | 24 (8%) | 10 (3%) | 315 (2%) | |
C55: UTERUS, NOS | 0 (0%) | 0 (0%) | 1 (1%) | 2 (1%) | 9 (6%) | 8 (6%) | 10 (7%) | 14 (10%) | 13 (9%) | 12 (8%) | 19 (13%) | 15 (10%) | 8 (6%) | 8 (6%) | 11 (8%) | 12 (8%) | 2 (1%) | 144 (1%) | |
C56: OVARY | 6 (1%) | 4 (1%) | 15 (2%) | 36 (5%) | 28 (4%) | 40 (5%) | 43 (6%) | 56 (7%) | 87 (12%) | 65 (9%) | 70 (9%) | 86 (11%) | 67 (9%) | 67 (9%) | 28 (4%) | 45 (6%) | 5 (1%) | 748 (4%) | |
C57: FEMALE GEN.- OTHER | 2 (18%) | 0 (0%) | 1 (9%) | 2 (18%) | 1 (9%) | 1 (9%) | 1 (9%) | 0 (0%) | 2 (18%) | 0 (0%) | 0 (0%) | 1 (9%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 11 (0.05%) | |
C58: PLACENTA | 0 (0%) | 0 (0%) | 0 (0%) | 3 (4%) | 15 (22%) | 14 (20%) | 19 (28%) | 3 (4%) | 11 (16%) | 2 (3%) | 1 (1%) | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 69 (0.3%) | |
C60: PENIS | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
C61: PROSTATE | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
C62: TESTIS | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
C63: MALE GEN.- OTHER | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (50%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (50%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (0.01%) | |
C64: KIDNEY | 120 (45%) | 59 (22%) | 5 (2%) | 3 (1%) | 2 (1%) | 3 (1%) | 3 (1%) | 4 (1%) | 12 (4%) | 9 (3%) | 13 (5%) | 16 (6%) | 5 (2%) | 7 (3%) | 0 (0%) | 5 (2%) | 1 (0.4%) | 267 (1%) | |
C65: RENAL PELVIS | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (50%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (50%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (0.01%) | |
C67: BLADDER | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) | 1 (1%) | 2 (2%) | 3 (4%) | 11 (13%) | 2 (2%) | 8 (10%) | 7 (9%) | 14 (17%) | 8 (10%) | 16 (20%) | 6 (7%) | 2 (2%) | 82 (0.4%) | |
C68: URETHRA, OTHER | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (17%) | 0 (0%) | 0 (0%) | 1 (17%) | 0 (0%) | 1 (17%) | 0 (0%) | 2 (33%) | 1 (17%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 6 (0.03%) | |
C69: EYE | 101 (41%) | 19 (8%) | 7 (3%) | 4 (2%) | 2 (1%) | 10 (4%) | 24 (10%) | 18 (7%) | 21 (9%) | 11 (4%) | 11 (4%) | 1 (0.4%) | 3 (1%) | 4 (2%) | 4 (2%) | 4 (2%) | 2 (1%) | 246 (1%) | |
C70-C72: BRAIN, NERVOUS SYSTEM | 19 (8%) | 20 (8%) | 20 (8%) | 12 (5%) | 8 (3%) | 14 (6%) | 21 (9%) | 17 (7%) | 12 (5%) | 6 (2%) | 17 (7%) | 28 (12%) | 15 (6%) | 15 (6%) | 9 (4%) | 5 (2%) | 3 (1%) | 241 (1%) | |
C73: THYROID | 0 (0%) | 1 (0.4%) | 2 (1%) | 8 (3%) | 12 (4%) | 15 (5%) | 21 (7%) | 24 (8%) | 32 (11%) | 23 (8%) | 44 (15%) | 20 (7%) | 22 (8%) | 19 (7%) | 14 (5%) | 18 (6%) | 10 (4%) | 285 (1%) | |
C74: ADRENAL GLAND | 2 (11%) | 2 (11%) | 3 (16%) | 4 (21%) | 2 (11%) | 1 (5%) | 2 (11%) | 2 (11%) | 0 (0%) | 1 (5%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 19 (0.09%) | |
C75: ENDOCRINE GLANDS | 0 (0%) | 1 (14%) | 0 (0%) | 0 (0%) | 1 (14%) | 0 (0%) | 0 (0%) | 1 (14%) | 1 (14%) | 1 (14%) | 0 (0%) | 0 (0%) | 1 (14%) | 1 (14%) | 0 (0%) | 0 (0%) | 0 (0%) | 7 (0.03%) | |
C76: ILL-DEFINED | 12 (7%) | 12 (7%) | 7 (4%) | 5 (3%) | 11 (6%) | 9 (5%) | 12 (7%) | 11 (6%) | 13 (8%) | 14 (8%) | 10 (6%) | 12 (7%) | 11 (6%) | 7 (4%) | 10 (6%) | 14 (8%) | 2 (1%) | 172 (1%) | |
C77: LYMPH NODES | 14 (9%) | 14 (9%) | 12 (7%) | 17 (11%) | 9 (6%) | 9 (6%) | 13 (8%) | 12 (7%) | 12 (7%) | 12 (7%) | 6 (4%) | 3 (2%) | 4 (2%) | 3 (2%) | 4 (2%) | 3 (2%) | 14 (9%) | 161 (1%) | |
C81-C85, C96: LYMPHOMA | 95 (10%) | 143 (15%) | 124 (13%) | 72 (7%) | 66 (7%) | 45 (5%) | 73 (7%) | 72 (7%) | 57 (6%) | 49 (5%) | 42 (4%) | 39 (4%) | 30 (3%) | 27 (3%) | 30 (3%) | 13 (1%) | 1 (0.1%) | 978 (5%) | |
C88: MULTIPLE MYELOMA | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (50%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (50%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (0.01%) | |
C90-C95: LEUKAEMIA | 70 (5%) | 116 (9%) | 108 (8%) | 92 (7%) | 68 (5%) | 70 (5%) | 74 (6%) | 65 (5%) | 65 (5%) | 101 (8%) | 101 (8%) | 110 (8%) | 109 (8%) | 67 (5%) | 64 (5%) | 56 (4%) | 0 (0%) | 1336 (7%) | |
OTHER | 0 (0%) | 0 (0%) | 0 (0%) | 1 (14%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (57%) | 0 (0%) | 2 (29%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 7 (0.03%) | |
UNKNOWN | 12 (1%) | 13 (1%) | 17 (1%) | 31 (3%) | 23 (2%) | 22 (2%) | 57 (5%) | 55 (4%) | 73 (6%) | 78 (6%) | 99 (8%) | 101 (8%) | 102 (8%) | 89 (7%) | 90 (7%) | 167 (14%) | 206 (17%) | 1235 (6%) | |
Total | 578 (3%) | 505 (2%) | 505 (2%) | 554 (3%) | 601 (3%) | 862 (4%) | 1461 (7%) | 1659 (8%) | 2138 (10%) | 1893 (9%) | 1902 (9%) | 1877 (9%) | 1760 (9%) | 1368 (7%) | 1145 (6%) | 1327 (6%) | 389 (2%) | 20524 (100%) | |
5.4.1.3 Male
Table X: Frequency and Proportions of all Cancer Types | Male | |||||||||||||||||||
label | variable | Age Group | Total | ||||||||||||||||
0-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | > 75 | Unknown | |||
ICD10 Site | C00: LIP | 0 (0%) | 1 (10%) | 0 (0%) | 0 (0%) | 1 (10%) | 0 (0%) | 0 (0%) | 2 (20%) | 2 (20%) | 0 (0%) | 1 (10%) | 0 (0%) | 1 (10%) | 1 (10%) | 1 (10%) | 0 (0%) | 0 (0%) | 10 (0.05%) |
C01-C02: TONGUE | 0 (0%) | 1 (1%) | 0 (0%) | 1 (1%) | 0 (0%) | 9 (6%) | 2 (1%) | 4 (2%) | 14 (9%) | 30 (19%) | 11 (7%) | 17 (11%) | 19 (12%) | 17 (11%) | 19 (12%) | 10 (6%) | 6 (4%) | 160 (1%) | |
C03-C06: MOUTH | 2 (2%) | 0 (0%) | 0 (0%) | 1 (1%) | 1 (1%) | 2 (2%) | 2 (2%) | 2 (2%) | 8 (10%) | 10 (12%) | 7 (9%) | 16 (20%) | 6 (8%) | 8 (10%) | 6 (8%) | 7 (9%) | 2 (2%) | 80 (0.4%) | |
C07-C08: SALIVARY GLANDS | 3 (4%) | 1 (1%) | 2 (2%) | 3 (4%) | 3 (4%) | 1 (1%) | 5 (6%) | 4 (5%) | 8 (10%) | 5 (6%) | 5 (6%) | 8 (10%) | 6 (7%) | 9 (11%) | 6 (7%) | 11 (13%) | 2 (2%) | 82 (0.4%) | |
C09: TONSILS | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (50%) | 0 (0%) | 0 (0%) | 1 (25%) | 1 (25%) | 0 (0%) | 0 (0%) | 0 (0%) | 4 (0.02%) | |
C10: OROPHARYNX | 0 (0%) | 0 (0%) | 1 (2%) | 1 (2%) | 1 (2%) | 4 (10%) | 1 (2%) | 1 (2%) | 4 (10%) | 5 (12%) | 6 (15%) | 4 (10%) | 5 (12%) | 4 (10%) | 2 (5%) | 2 (5%) | 0 (0%) | 41 (0.2%) | |
C11: NASOPHARYNX | 2 (0.3%) | 8 (1%) | 45 (7%) | 65 (11%) | 50 (8%) | 33 (5%) | 38 (6%) | 33 (5%) | 56 (9%) | 67 (11%) | 64 (10%) | 41 (7%) | 48 (8%) | 27 (4%) | 14 (2%) | 19 (3%) | 9 (1%) | 619 (3%) | |
C12-C13: HYPOPHARYNX | 0 (0%) | 0 (0%) | 0 (0%) | 5 (10%) | 4 (8%) | 4 (8%) | 0 (0%) | 0 (0%) | 4 (8%) | 2 (4%) | 6 (12%) | 4 (8%) | 9 (17%) | 4 (8%) | 3 (6%) | 5 (10%) | 2 (4%) | 52 (0.3%) | |
C14: OTHER PHARYNX | 1 (2%) | 0 (0%) | 1 (2%) | 1 (2%) | 1 (2%) | 1 (2%) | 1 (2%) | 2 (4%) | 4 (8%) | 6 (12%) | 10 (20%) | 8 (16%) | 6 (12%) | 4 (8%) | 4 (8%) | 1 (2%) | 0 (0%) | 51 (0.3%) | |
C15: ESOPHAGUS | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 9 (0.4%) | 34 (2%) | 47 (2%) | 82 (4%) | 127 (6%) | 205 (10%) | 254 (12%) | 303 (15%) | 300 (14%) | 233 (11%) | 224 (11%) | 265 (13%) | 0 (0%) | 2083 (11%) | |
C16: STOMACH | 0 (0%) | 0 (0%) | 2 (0.3%) | 6 (1%) | 11 (2%) | 5 (1%) | 22 (3%) | 31 (4%) | 35 (5%) | 42 (6%) | 61 (9%) | 81 (11%) | 99 (14%) | 89 (13%) | 83 (12%) | 128 (18%) | 16 (2%) | 711 (4%) | |
C17: SMALL INTESTINE | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (4%) | 1 (4%) | 1 (4%) | 4 (14%) | 6 (21%) | 3 (11%) | 3 (11%) | 5 (18%) | 1 (4%) | 3 (11%) | 0 (0%) | 28 (0.2%) | |
C18: COLON | 0 (0%) | 0 (0%) | 1 (0.2%) | 8 (2%) | 6 (1%) | 17 (4%) | 28 (6%) | 26 (6%) | 28 (6%) | 43 (9%) | 50 (11%) | 62 (13%) | 66 (14%) | 31 (7%) | 45 (10%) | 41 (9%) | 16 (3%) | 468 (3%) | |
C19-C20: HYPOPHARYNX | 0 (0%) | 0 (0%) | 0 (0%) | 7 (2%) | 5 (1%) | 14 (4%) | 19 (5%) | 24 (7%) | 39 (11%) | 26 (7%) | 39 (11%) | 36 (10%) | 47 (13%) | 38 (11%) | 31 (9%) | 29 (8%) | 4 (1%) | 358 (2%) | |
C21: ANUS | 0 (0%) | 0 (0%) | 0 (0%) | 1 (2%) | 2 (3%) | 4 (6%) | 3 (5%) | 5 (8%) | 5 (8%) | 3 (5%) | 4 (6%) | 8 (13%) | 8 (13%) | 4 (6%) | 7 (11%) | 8 (13%) | 1 (2%) | 63 (0.3%) | |
C22: LIVER | 7 (1%) | 1 (0.1%) | 5 (1%) | 11 (2%) | 19 (3%) | 25 (4%) | 47 (7%) | 63 (9%) | 78 (11%) | 67 (9%) | 69 (10%) | 67 (9%) | 68 (10%) | 54 (8%) | 54 (8%) | 57 (8%) | 18 (3%) | 710 (4%) | |
C23-C24: GALL BLADDER | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (3%) | 1 (3%) | 3 (8%) | 1 (3%) | 3 (8%) | 5 (14%) | 8 (22%) | 3 (8%) | 7 (19%) | 4 (11%) | 0 (0%) | 36 (0.2%) | |
C25: PANCREAS | 0 (0%) | 0 (0%) | 1 (0.3%) | 1 (0.3%) | 0 (0%) | 3 (1%) | 10 (3%) | 12 (4%) | 20 (7%) | 29 (10%) | 23 (8%) | 42 (14%) | 37 (12%) | 38 (12%) | 41 (13%) | 41 (13%) | 6 (2%) | 304 (2%) | |
C26: GASTROINTESTINAL | 0 (0%) | 0 (0%) | 1 (5%) | 0 (0%) | 2 (11%) | 0 (0%) | 0 (0%) | 2 (11%) | 2 (11%) | 2 (11%) | 0 (0%) | 3 (16%) | 1 (5%) | 3 (16%) | 3 (16%) | 0 (0%) | 0 (0%) | 19 (0.1%) | |
C30-C31: SINUSES, NOSE, ETC | 2 (3%) | 1 (2%) | 2 (3%) | 3 (5%) | 4 (6%) | 3 (5%) | 4 (6%) | 3 (5%) | 10 (15%) | 5 (8%) | 5 (8%) | 5 (8%) | 8 (12%) | 7 (11%) | 0 (0%) | 1 (2%) | 3 (5%) | 66 (0.4%) | |
C32: LARYNX | 0 (0%) | 0 (0%) | 0 (0%) | 1 (0.5%) | 7 (3%) | 0 (0%) | 2 (1%) | 8 (4%) | 7 (3%) | 16 (7%) | 25 (12%) | 29 (13%) | 44 (20%) | 23 (11%) | 29 (13%) | 22 (10%) | 4 (2%) | 217 (1%) | |
C33-C34: TRACHEA, BRONCHUS, LUNG | 0 (0%) | 0 (0%) | 1 (0.3%) | 2 (1%) | 2 (1%) | 7 (2%) | 8 (3%) | 10 (3%) | 21 (7%) | 19 (6%) | 29 (9%) | 40 (13%) | 43 (14%) | 37 (12%) | 43 (14%) | 31 (10%) | 14 (5%) | 307 (2%) | |
C37-C38: THYMUS | 0 (0%) | 0 (0%) | 1 (3%) | 2 (6%) | 1 (3%) | 2 (6%) | 1 (3%) | 5 (14%) | 1 (3%) | 4 (11%) | 2 (6%) | 2 (6%) | 4 (11%) | 3 (9%) | 3 (9%) | 4 (11%) | 0 (0%) | 35 (0.2%) | |
C39: RESPIRATORY TRACT | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
C40-C41: BONES - LIMBS | 8 (2%) | 21 (6%) | 55 (16%) | 89 (26%) | 38 (11%) | 21 (6%) | 19 (5%) | 19 (5%) | 8 (2%) | 9 (3%) | 15 (4%) | 9 (3%) | 12 (3%) | 6 (2%) | 8 (2%) | 7 (2%) | 5 (1%) | 349 (2%) | |
C42: BLOOD, SPLEEN | 34 (7%) | 34 (7%) | 60 (12%) | 27 (5%) | 21 (4%) | 25 (5%) | 32 (6%) | 19 (4%) | 28 (6%) | 22 (4%) | 19 (4%) | 38 (8%) | 25 (5%) | 31 (6%) | 27 (5%) | 31 (6%) | 25 (5%) | 498 (3%) | |
C43: MELANOMA OF SKIN | 1 (1%) | 2 (2%) | 2 (2%) | 1 (1%) | 2 (2%) | 2 (2%) | 3 (3%) | 6 (5%) | 8 (7%) | 9 (8%) | 13 (11%) | 16 (14%) | 11 (9%) | 16 (14%) | 7 (6%) | 18 (15%) | 0 (0%) | 117 (1%) | |
C44: OTHER SKIN | 3 (1%) | 3 (1%) | 7 (1%) | 11 (2%) | 15 (3%) | 34 (7%) | 47 (10%) | 43 (9%) | 39 (8%) | 45 (9%) | 43 (9%) | 32 (7%) | 39 (8%) | 31 (6%) | 29 (6%) | 47 (10%) | 17 (4%) | 485 (3%) | |
C45: KAPOSISARCOMA | 20 (1%) | 33 (2%) | 24 (2%) | 29 (2%) | 42 (3%) | 149 (9%) | 317 (20%) | 295 (19%) | 230 (14%) | 156 (10%) | 113 (7%) | 66 (4%) | 44 (3%) | 26 (2%) | 29 (2%) | 19 (1%) | 0 (0%) | 1592 (9%) | |
C47-C49: CONNECTIVE & SOFT TISSUE | 54 (10%) | 36 (7%) | 45 (8%) | 53 (10%) | 40 (7%) | 25 (5%) | 45 (8%) | 40 (7%) | 27 (5%) | 39 (7%) | 19 (3%) | 32 (6%) | 31 (6%) | 22 (4%) | 13 (2%) | 14 (3%) | 13 (2%) | 548 (3%) | |
C50: BREAST | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (0.5%) | 3 (1%) | 1 (0.5%) | 17 (8%) | 16 (8%) | 22 (11%) | 20 (10%) | 17 (8%) | 35 (17%) | 26 (13%) | 21 (10%) | 24 (12%) | 0 (0%) | 203 (1%) | |
C51: VULVA | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
C52: VAGINA | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
C53: CERVIX UTERI | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
C54: CORPUS UTERI | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
C55: UTERUS, NOS | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
C56: OVARY | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (50%) | 1 (50%) | 0 (0%) | 2 (0.01%) | |
C57: FEMALE GEN.- OTHER | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
C58: PLACENTA | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
C60: PENIS | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) | 1 (1%) | 8 (8%) | 11 (11%) | 12 (12%) | 14 (14%) | 12 (12%) | 10 (10%) | 5 (5%) | 8 (8%) | 9 (9%) | 6 (6%) | 1 (1%) | 98 (1%) | |
C61: PROSTATE | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (0.1%) | 2 (0.1%) | 4 (0.2%) | 4 (0.2%) | 5 (0.2%) | 19 (1%) | 46 (2%) | 132 (7%) | 280 (14%) | 384 (19%) | 466 (23%) | 681 (34%) | 0 (0%) | 2025 (11%) | |
C62: TESTIS | 3 (6%) | 3 (6%) | 0 (0%) | 6 (12%) | 5 (10%) | 3 (6%) | 7 (13%) | 1 (2%) | 4 (8%) | 4 (8%) | 1 (2%) | 6 (12%) | 2 (4%) | 2 (4%) | 0 (0%) | 4 (8%) | 1 (2%) | 52 (0.3%) | |
C63: MALE GEN.- OTHER | 0 (0%) | 1 (10%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (10%) | 0 (0%) | 4 (40%) | 0 (0%) | 1 (10%) | 0 (0%) | 1 (10%) | 1 (10%) | 1 (10%) | 10 (0.05%) | |
C64: KIDNEY | 152 (46%) | 64 (19%) | 15 (5%) | 5 (2%) | 2 (1%) | 5 (2%) | 5 (2%) | 7 (2%) | 12 (4%) | 5 (2%) | 3 (1%) | 11 (3%) | 8 (2%) | 18 (5%) | 5 (2%) | 7 (2%) | 5 (2%) | 329 (2%) | |
C65: RENAL PELVIS | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (33%) | 0 (0%) | 1 (33%) | 0 (0%) | 1 (33%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (0.02%) | |
C67: BLADDER | 2 (1%) | 0 (0%) | 2 (1%) | 0 (0%) | 2 (1%) | 1 (1%) | 5 (3%) | 6 (3%) | 10 (6%) | 13 (7%) | 12 (7%) | 18 (10%) | 23 (13%) | 32 (18%) | 19 (11%) | 29 (16%) | 5 (3%) | 179 (1%) | |
C68: URETHRA, OTHER | 0 (0%) | 2 (20%) | 0 (0%) | 0 (0%) | 1 (10%) | 1 (10%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (10%) | 1 (10%) | 0 (0%) | 2 (20%) | 1 (10%) | 0 (0%) | 1 (10%) | 0 (0%) | 10 (0.05%) | |
C69: EYE | 105 (40%) | 32 (12%) | 6 (2%) | 2 (1%) | 5 (2%) | 6 (2%) | 9 (3%) | 15 (6%) | 22 (8%) | 16 (6%) | 9 (3%) | 6 (2%) | 10 (4%) | 8 (3%) | 5 (2%) | 2 (1%) | 6 (2%) | 264 (1%) | |
C70-C72: BRAIN, NERVOUS SYSTEM | 24 (8%) | 27 (9%) | 19 (6%) | 19 (6%) | 22 (7%) | 13 (4%) | 14 (5%) | 22 (7%) | 20 (7%) | 23 (8%) | 32 (11%) | 19 (6%) | 13 (4%) | 15 (5%) | 11 (4%) | 8 (3%) | 1 (0.3%) | 302 (2%) | |
C73: THYROID | 0 (0%) | 0 (0%) | 1 (1%) | 1 (1%) | 1 (1%) | 2 (2%) | 1 (1%) | 5 (5%) | 10 (9%) | 14 (13%) | 15 (14%) | 12 (11%) | 16 (15%) | 15 (14%) | 5 (5%) | 8 (7%) | 4 (4%) | 110 (1%) | |
C74: ADRENAL GLAND | 5 (33%) | 4 (27%) | 1 (7%) | 1 (7%) | 0 (0%) | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (7%) | 1 (7%) | 0 (0%) | 0 (0%) | 1 (7%) | 0 (0%) | 0 (0%) | 0 (0%) | 15 (0.08%) | |
C75: ENDOCRINE GLANDS | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (14%) | 2 (29%) | 1 (14%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (14%) | 2 (29%) | 0 (0%) | 0 (0%) | 7 (0.04%) | |
C76: ILL-DEFINED | 13 (7%) | 12 (7%) | 11 (6%) | 9 (5%) | 7 (4%) | 8 (4%) | 9 (5%) | 10 (6%) | 13 (7%) | 10 (6%) | 12 (7%) | 16 (9%) | 13 (7%) | 17 (9%) | 6 (3%) | 10 (6%) | 3 (2%) | 179 (1%) | |
C77: LYMPH NODES | 16 (6%) | 37 (15%) | 34 (14%) | 25 (10%) | 13 (5%) | 11 (4%) | 11 (4%) | 11 (4%) | 12 (5%) | 10 (4%) | 16 (6%) | 9 (4%) | 9 (4%) | 9 (4%) | 4 (2%) | 6 (2%) | 18 (7%) | 251 (1%) | |
C81-C85, C96: LYMPHOMA | 163 (10%) | 277 (17%) | 237 (15%) | 162 (10%) | 66 (4%) | 74 (5%) | 71 (4%) | 64 (4%) | 94 (6%) | 89 (6%) | 63 (4%) | 68 (4%) | 60 (4%) | 35 (2%) | 35 (2%) | 37 (2%) | 0 (0%) | 1595 (9%) | |
C88: MULTIPLE MYELOMA | 0 (0%) | 1 (50%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (50%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (0.01%) | |
C90-C95: LEUKAEMIA | 106 (6%) | 167 (10%) | 164 (10%) | 94 (6%) | 75 (4%) | 77 (5%) | 100 (6%) | 69 (4%) | 97 (6%) | 96 (6%) | 117 (7%) | 116 (7%) | 105 (6%) | 107 (6%) | 85 (5%) | 102 (6%) | 0 (0%) | 1677 (9%) | |
OTHER | 0 (0%) | 0 (0%) | 0 (0%) | 1 (7%) | 0 (0%) | 1 (7%) | 2 (14%) | 0 (0%) | 2 (14%) | 2 (14%) | 0 (0%) | 1 (7%) | 0 (0%) | 2 (14%) | 0 (0%) | 3 (21%) | 0 (0%) | 14 (0.08%) | |
UNKNOWN | 21 (2%) | 16 (1%) | 23 (2%) | 43 (4%) | 22 (2%) | 26 (2%) | 29 (2%) | 39 (3%) | 62 (5%) | 69 (6%) | 78 (7%) | 84 (7%) | 109 (9%) | 113 (10%) | 86 (7%) | 199 (17%) | 147 (13%) | 1166 (6%) | |
Total | 747 (4%) | 785 (4%) | 769 (4%) | 697 (4%) | 512 (3%) | 660 (4%) | 983 (5%) | 1026 (6%) | 1209 (7%) | 1283 (7%) | 1344 (7%) | 1503 (8%) | 1690 (9%) | 1569 (8%) | 1500 (8%) | 1954 (11%) | 355 (2%) | 18586 (100%) | |
5.4.2 Trends of Cancer Incidence over Time
5.4.2.1 All Gender
5.4.2.2 Top 5 in Male
5.4.2.3 Top 5 in Female
5.5 Clinical Factors Analysis
5.5.1 Basis of Diagnosis Distribution
5.5.1.1 By Gender
5.5.1.2 Trends over time
5.5.1.3 By Age Group
Table X: Name of table | |||||||||||||||||||
label | variable | Age Group | Total | ||||||||||||||||
0-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | > 75 | Unknown | |||
Basis of Diagnosis | Autopsy with Histology | 1 (5%) | 0 (0%) | 0 (0%) | 2 (10%) | 1 (5%) | 0 (0%) | 0 (0%) | 2 (10%) | 1 (5%) | 2 (10%) | 2 (10%) | 2 (10%) | 1 (5%) | 2 (10%) | 1 (5%) | 3 (15%) | 0 (0%) | 20 (0.05%) |
Biochem./Immuno. test | 1 (1%) | 1 (1%) | 1 (1%) | 2 (1%) | 2 (1%) | 2 (1%) | 0 (0%) | 0 (0%) | 2 (1%) | 2 (1%) | 5 (3%) | 13 (7%) | 22 (11%) | 27 (14%) | 41 (21%) | 73 (37%) | 1 (1%) | 195 (0.5%) | |
Clin.Invest./Ult.Sound | 74 (3%) | 52 (2%) | 31 (1%) | 40 (2%) | 49 (2%) | 80 (3%) | 112 (5%) | 144 (6%) | 176 (7%) | 179 (8%) | 209 (9%) | 198 (8%) | 236 (10%) | 201 (9%) | 224 (9%) | 343 (15%) | 10 (0.4%) | 2358 (6%) | |
Clinical only | 6 (1%) | 8 (1%) | 7 (1%) | 8 (1%) | 10 (2%) | 28 (5%) | 43 (8%) | 42 (8%) | 54 (10%) | 36 (7%) | 51 (9%) | 47 (9%) | 44 (8%) | 45 (8%) | 47 (9%) | 63 (12%) | 7 (1%) | 546 (1%) | |
Cytology/Haemotology | 340 (6%) | 489 (9%) | 420 (8%) | 292 (5%) | 236 (4%) | 238 (4%) | 317 (6%) | 310 (6%) | 358 (7%) | 389 (7%) | 389 (7%) | 368 (7%) | 385 (7%) | 301 (5%) | 280 (5%) | 306 (6%) | 55 (1%) | 5473 (14%) | |
Death Certificate Only | 27 (2%) | 28 (2%) | 17 (1%) | 28 (2%) | 32 (2%) | 37 (3%) | 46 (4%) | 62 (5%) | 68 (5%) | 79 (6%) | 84 (6%) | 100 (8%) | 129 (10%) | 119 (9%) | 128 (10%) | 313 (24%) | 0 (0%) | 1297 (3%) | |
Histology metastases | 1 (2%) | 0 (0%) | 0 (0%) | 2 (3%) | 4 (7%) | 2 (3%) | 5 (8%) | 6 (10%) | 6 (10%) | 3 (5%) | 7 (12%) | 5 (8%) | 6 (10%) | 5 (8%) | 3 (5%) | 5 (8%) | 0 (0%) | 60 (0.2%) | |
Histology of primary | 871 (3%) | 710 (2%) | 795 (3%) | 874 (3%) | 776 (3%) | 1130 (4%) | 1912 (7%) | 2109 (7%) | 2664 (9%) | 2476 (9%) | 2482 (9%) | 2628 (9%) | 2615 (9%) | 2229 (8%) | 1910 (7%) | 2161 (7%) | 668 (2%) | 29010 (74%) | |
Surgery/Autopsy | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (6%) | 2 (11%) | 2 (11%) | 2 (11%) | 2 (11%) | 1 (6%) | 1 (6%) | 1 (6%) | 1 (6%) | 2 (11%) | 3 (17%) | 0 (0%) | 18 (0.05%) | |
Unknown | 1 (1%) | 1 (1%) | 3 (3%) | 3 (3%) | 2 (2%) | 3 (3%) | 7 (6%) | 7 (6%) | 14 (12%) | 8 (7%) | 12 (10%) | 17 (15%) | 11 (10%) | 6 (5%) | 7 (6%) | 11 (10%) | 2 (2%) | 115 (0.3%) | |
Total | 1322 (3%) | 1289 (3%) | 1274 (3%) | 1251 (3%) | 1112 (3%) | 1521 (4%) | 2444 (6%) | 2684 (7%) | 3345 (9%) | 3176 (8%) | 3242 (8%) | 3379 (9%) | 3450 (9%) | 2936 (8%) | 2643 (7%) | 3281 (8%) | 743 (2%) | 39092 (100%) | |
5.5.2 Staging Distribution
5.5.2.1 By Gender
5.5.2.2 Trends over time
5.5.2.3 By Age Group
Table X: Name of table | |||||||||||||||||||
label | variable | Age Group | Total | ||||||||||||||||
0-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | > 75 | Unknown | |||
Stage | In Situ | 3 (15%) | 1 (5%) | 0 (0%) | 1 (5%) | 3 (15%) | 1 (5%) | 2 (10%) | 0 (0%) | 2 (10%) | 3 (15%) | 1 (5%) | 0 (0%) | 2 (10%) | 0 (0%) | 0 (0%) | 1 (5%) | 0 (0%) | 20 (0.1%) |
Stage I | 8 (1%) | 14 (3%) | 19 (3%) | 11 (2%) | 13 (2%) | 22 (4%) | 38 (7%) | 68 (12%) | 103 (18%) | 76 (14%) | 51 (9%) | 48 (9%) | 35 (6%) | 26 (5%) | 12 (2%) | 13 (2%) | 2 (0.4%) | 559 (3%) | |
Stage II | 31 (3%) | 26 (2%) | 19 (2%) | 14 (1%) | 15 (1%) | 40 (3%) | 80 (7%) | 107 (9%) | 174 (15%) | 114 (10%) | 136 (11%) | 146 (12%) | 110 (9%) | 69 (6%) | 73 (6%) | 35 (3%) | 3 (0.3%) | 1192 (6%) | |
Stage III | 88 (4%) | 89 (4%) | 72 (3%) | 46 (2%) | 41 (2%) | 81 (3%) | 167 (7%) | 191 (8%) | 292 (12%) | 239 (10%) | 248 (10%) | 269 (11%) | 246 (10%) | 143 (6%) | 129 (5%) | 111 (5%) | 4 (0.2%) | 2456 (12%) | |
Stage IV | 55 (1%) | 58 (1%) | 75 (2%) | 110 (2%) | 89 (2%) | 124 (3%) | 218 (5%) | 260 (6%) | 354 (8%) | 357 (8%) | 394 (9%) | 505 (11%) | 506 (11%) | 500 (11%) | 393 (9%) | 414 (9%) | 55 (1%) | 4467 (22%) | |
Unknown | 521 (4%) | 445 (4%) | 456 (4%) | 424 (4%) | 337 (3%) | 471 (4%) | 692 (6%) | 777 (7%) | 945 (8%) | 958 (8%) | 962 (8%) | 1077 (9%) | 1055 (9%) | 881 (7%) | 780 (7%) | 938 (8%) | 52 (0.4%) | 11771 (58%) | |
Total | 706 (3%) | 633 (3%) | 641 (3%) | 606 (3%) | 498 (2%) | 739 (4%) | 1197 (6%) | 1403 (7%) | 1870 (9%) | 1747 (9%) | 1792 (9%) | 2045 (10%) | 1954 (10%) | 1619 (8%) | 1387 (7%) | 1512 (7%) | 116 (1%) | 20465 (100%) | |
5.5.3 Concurrent Illness
5.5.3.1 By Gender
5.5.3.2 By Age Group
Table X: Name of table | |||||||||||||||||||
label | variable | Age Group | Total | ||||||||||||||||
0-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | > 75 | Unknown | |||
Concurrent Illness | ABSENT | 161 (3%) | 157 (3%) | 184 (4%) | 186 (4%) | 136 (3%) | 193 (4%) | 274 (6%) | 349 (7%) | 443 (9%) | 410 (8%) | 446 (9%) | 475 (10%) | 470 (10%) | 362 (7%) | 283 (6%) | 336 (7%) | 3 (0.06%) | 4868 (12%) |
PRESENT | 17 (1%) | 50 (2%) | 38 (1%) | 54 (2%) | 87 (3%) | 276 (8%) | 525 (16%) | 510 (16%) | 527 (16%) | 418 (13%) | 288 (9%) | 207 (6%) | 113 (3%) | 73 (2%) | 51 (2%) | 36 (1%) | 7 (0.2%) | 3277 (8%) | |
Unknown | 1141 (4%) | 1074 (3%) | 1044 (3%) | 1004 (3%) | 887 (3%) | 1045 (3%) | 1639 (5%) | 1824 (6%) | 2364 (8%) | 2337 (8%) | 2502 (8%) | 2682 (9%) | 2856 (9%) | 2491 (8%) | 2297 (7%) | 2896 (9%) | 718 (2%) | 30801 (79%) | |
Total | 1319 (3%) | 1281 (3%) | 1266 (3%) | 1244 (3%) | 1110 (3%) | 1514 (4%) | 2438 (6%) | 2683 (7%) | 3334 (9%) | 3165 (8%) | 3236 (8%) | 3364 (9%) | 3439 (9%) | 2926 (8%) | 2631 (7%) | 3268 (8%) | 728 (2%) | 38946 (100%) | |
5.5.4 Types of treatment
5.5.4.1 By Gender
5.5.4.2 Trends over time
5.5.4.3 By Age Group
Table X: Name of table | |||||||||||||||||||
label | variable | Age Group | Total | ||||||||||||||||
0-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | > 75 | Unknown | |||
Type of Treatment | Chemo Therapy Only | 519 (7%) | 497 (7%) | 451 (6%) | 350 (5%) | 244 (3%) | 330 (4%) | 524 (7%) | 567 (8%) | 634 (8%) | 572 (8%) | 583 (8%) | 615 (8%) | 561 (7%) | 438 (6%) | 320 (4%) | 293 (4%) | 6 (0.08%) | 7504 (19%) |
Hormonal + Chemo Therapy | 2 (1%) | 4 (1%) | 2 (1%) | 3 (1%) | 4 (1%) | 9 (2%) | 15 (4%) | 13 (3%) | 26 (7%) | 35 (9%) | 24 (6%) | 34 (9%) | 55 (14%) | 54 (14%) | 67 (17%) | 52 (13%) | 0 (0%) | 399 (1%) | |
Hormonal Therapy Only | 0 (0%) | 2 (1%) | 1 (0.3%) | 0 (0%) | 2 (1%) | 0 (0%) | 2 (1%) | 6 (2%) | 1 (0.3%) | 8 (2%) | 6 (2%) | 20 (6%) | 49 (15%) | 58 (17%) | 83 (25%) | 98 (29%) | 1 (0.3%) | 337 (1%) | |
Radio + Chemo + Hormonal Therapy | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (3%) | 0 (0%) | 6 (6%) | 4 (4%) | 5 (5%) | 6 (6%) | 6 (6%) | 7 (7%) | 11 (11%) | 25 (25%) | 14 (14%) | 12 (12%) | 0 (0%) | 99 (0.3%) | |
Radio + Chemo Therapy | 16 (1%) | 21 (1%) | 27 (2%) | 58 (4%) | 35 (2%) | 35 (2%) | 85 (6%) | 93 (7%) | 145 (10%) | 139 (10%) | 163 (12%) | 170 (12%) | 176 (13%) | 120 (9%) | 78 (6%) | 40 (3%) | 2 (0.1%) | 1403 (4%) | |
Radio + Hormonal Therapy | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) | 0 (0%) | 1 (1%) | 2 (2%) | 3 (3%) | 15 (15%) | 17 (17%) | 18 (18%) | 18 (18%) | 24 (24%) | 1 (1%) | 100 (0.3%) | |
Radio Therapy Only | 2 (0.5%) | 6 (1%) | 8 (2%) | 10 (2%) | 7 (2%) | 18 (4%) | 25 (6%) | 19 (4%) | 39 (9%) | 40 (9%) | 36 (8%) | 47 (11%) | 51 (12%) | 40 (9%) | 32 (8%) | 46 (11%) | 0 (0%) | 426 (1%) | |
Surgery + Chemo + Hormonal Therapy | 2 (1%) | 0 (0%) | 0 (0%) | 3 (1%) | 2 (1%) | 5 (2%) | 13 (6%) | 24 (10%) | 24 (10%) | 26 (11%) | 18 (8%) | 25 (11%) | 23 (10%) | 26 (11%) | 16 (7%) | 29 (12%) | 0 (0%) | 236 (1%) | |
Surgery + Chemo Therapy | 107 (7%) | 58 (4%) | 56 (3%) | 44 (3%) | 36 (2%) | 54 (3%) | 93 (6%) | 139 (9%) | 160 (10%) | 136 (8%) | 162 (10%) | 174 (11%) | 149 (9%) | 114 (7%) | 81 (5%) | 69 (4%) | 1 (0.06%) | 1633 (4%) | |
Surgery + Hormonal Therapy | 0 (0%) | 0 (0%) | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1%) | 0 (0%) | 2 (2%) | 3 (4%) | 3 (4%) | 6 (7%) | 14 (17%) | 17 (20%) | 17 (20%) | 19 (23%) | 0 (0%) | 83 (0.2%) | |
Surgery + Radio + Chemo + Hormonal Therapy | 1 (0.5%) | 0 (0%) | 0 (0%) | 2 (1%) | 2 (1%) | 8 (4%) | 15 (7%) | 21 (10%) | 41 (19%) | 26 (12%) | 25 (11%) | 21 (10%) | 27 (12%) | 16 (7%) | 6 (3%) | 10 (5%) | 0 (0%) | 221 (1%) | |
Surgery + Radio + Chemo Therapy | 35 (7%) | 22 (4%) | 11 (2%) | 6 (1%) | 7 (1%) | 17 (3%) | 33 (6%) | 53 (10%) | 64 (12%) | 58 (11%) | 47 (9%) | 70 (13%) | 45 (8%) | 33 (6%) | 26 (5%) | 2 (0.4%) | 1 (0.2%) | 530 (1%) | |
Surgery + Radio + Hormonal Therapy | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (3%) | 3 (10%) | 1 (3%) | 2 (7%) | 1 (3%) | 4 (13%) | 5 (17%) | 4 (13%) | 9 (30%) | 0 (0%) | 30 (0.08%) | |
Surgery + Radio Therapy | 1 (1%) | 2 (2%) | 3 (3%) | 1 (1%) | 2 (2%) | 2 (2%) | 3 (3%) | 6 (7%) | 12 (13%) | 8 (9%) | 9 (10%) | 10 (11%) | 10 (11%) | 9 (10%) | 3 (3%) | 11 (12%) | 0 (0%) | 92 (0.2%) | |
Surgery Only | 33 (2%) | 22 (1%) | 31 (1%) | 66 (3%) | 49 (2%) | 88 (4%) | 139 (6%) | 152 (7%) | 211 (10%) | 201 (9%) | 197 (9%) | 192 (9%) | 220 (10%) | 200 (9%) | 171 (8%) | 202 (9%) | 13 (1%) | 2187 (6%) | |
Unknown | 607 (3%) | 656 (3%) | 683 (3%) | 708 (3%) | 720 (3%) | 956 (4%) | 1489 (6%) | 1587 (7%) | 1979 (8%) | 1915 (8%) | 1962 (8%) | 1973 (8%) | 2038 (9%) | 1764 (7%) | 1709 (7%) | 2365 (10%) | 719 (3%) | 23830 (61%) | |
Total | 1325 (3%) | 1290 (3%) | 1274 (3%) | 1251 (3%) | 1113 (3%) | 1522 (4%) | 2444 (6%) | 2685 (7%) | 3347 (9%) | 3176 (8%) | 3246 (8%) | 3380 (9%) | 3450 (9%) | 2937 (8%) | 2645 (7%) | 3281 (8%) | 744 (2%) | 39110 (100%) | |
5.6 Key Cancer Types of Interest
Focus on: Breast, Cervix, Prostate, Esophagus, Lymphomas, Leukemias
5.6.1 BREAST (C50)
5.6.1.1 Age / Gender Distribution
Table X: Name of table | ||||
label | variable | Sex | Total | |
Female | Male | |||
Age Group | 0-4 | 0 (NA%) | 0 (NA%) | 0 (0%) |
5-9 | 0 (NA%) | 0 (NA%) | 0 (0%) | |
10-14 | 0 (NA%) | 0 (NA%) | 0 (0%) | |
15-19 | 22 (100%) | 0 (0%) | 22 (1%) | |
20-24 | 54 (98%) | 1 (2%) | 55 (2%) | |
25-29 | 128 (98%) | 3 (2%) | 131 (4%) | |
30-34 | 272 (100%) | 1 (0.4%) | 273 (8%) | |
35-39 | 393 (96%) | 17 (4%) | 410 (12%) | |
40-44 | 504 (97%) | 16 (3%) | 520 (15%) | |
45-49 | 426 (95%) | 22 (5%) | 448 (13%) | |
50-54 | 392 (95%) | 20 (5%) | 412 (12%) | |
55-59 | 314 (95%) | 17 (5%) | 331 (9%) | |
60-64 | 291 (89%) | 35 (11%) | 326 (9%) | |
65-69 | 193 (88%) | 26 (12%) | 219 (6%) | |
70-74 | 144 (87%) | 21 (13%) | 165 (5%) | |
> 75 | 179 (88%) | 24 (12%) | 203 (6%) | |
Unknown | 0 (NA%) | 0 (NA%) | 0 (0%) | |
Total | 3312 (94%) | 203 (6%) | 3515 (100%) | |
5.6.1.1.1 Trends over time
5.6.1.2 Distribution of common subsites
5.6.1.2.1 Trends over time
5.6.1.3 Basis of Diagnosis Distribution
5.6.1.3.1 By Gender
5.6.1.3.2 Trends over time
5.6.1.4 Staging Distribution
5.6.1.4.1 Trends over time
5.6.1.5 Types of treatment
5.6.1.5.1 Trends over time
5.6.2 CERVIX (C53)
5.6.2.1 Age / Gender Distribution
Table X: Name of table | ||||
label | variable | Sex | Total | |
Female | Male | |||
Age Group | 0-4 | 0 (0%) | 0 (NA%) | 0 (0%) |
5-9 | 0 (0%) | 0 (NA%) | 0 (0%) | |
10-14 | 0 (0%) | 0 (NA%) | 0 (0%) | |
15-19 | 10 (0.3%) | 0 (NA%) | 10 (0.3%) | |
20-24 | 26 (1%) | 0 (NA%) | 26 (1%) | |
25-29 | 115 (3%) | 0 (NA%) | 115 (3%) | |
30-34 | 257 (7%) | 0 (NA%) | 257 (7%) | |
35-39 | 402 (11%) | 0 (NA%) | 402 (11%) | |
40-44 | 582 (15%) | 0 (NA%) | 582 (15%) | |
45-49 | 514 (14%) | 0 (NA%) | 514 (14%) | |
50-54 | 477 (13%) | 0 (NA%) | 477 (13%) | |
55-59 | 434 (11%) | 0 (NA%) | 434 (11%) | |
60-64 | 373 (10%) | 0 (NA%) | 373 (10%) | |
65-69 | 238 (6%) | 0 (NA%) | 238 (6%) | |
70-74 | 188 (5%) | 0 (NA%) | 188 (5%) | |
> 75 | 174 (5%) | 0 (NA%) | 174 (5%) | |
Unknown | 0 (0%) | 0 (NA%) | 0 (0%) | |
Total | 3790 (100%) | 0 (0%) | 3790 (100%) | |
5.6.2.1.1 Trends over time
5.6.2.2 Distribution of common subsites
5.6.2.2.1 Trends over time
5.6.2.3 Basis of Diagnosis Distribution
5.6.2.3.1 By Gender
5.6.2.3.2 Trends over time
5.6.2.4 Staging Distribution
5.6.2.4.1 Trends over time
5.6.2.5 Types of treatment
5.6.2.5.1 Trends over time
5.6.3 PROSTATE (C61)
5.6.3.1 Age / Gender Distribution
Table X: Name of table | ||||
label | variable | Sex | Total | |
Female | Male | |||
Age Group | 0-4 | 0 (NA%) | 0 (0%) | 0 (0%) |
5-9 | 0 (NA%) | 0 (0%) | 0 (0%) | |
10-14 | 0 (NA%) | 0 (0%) | 0 (0%) | |
15-19 | 0 (NA%) | 0 (0%) | 0 (0%) | |
20-24 | 0 (NA%) | 2 (0.1%) | 2 (0.1%) | |
25-29 | 0 (NA%) | 2 (0.1%) | 2 (0.1%) | |
30-34 | 0 (NA%) | 4 (0.2%) | 4 (0.2%) | |
35-39 | 0 (NA%) | 4 (0.2%) | 4 (0.2%) | |
40-44 | 0 (NA%) | 5 (0.2%) | 5 (0.2%) | |
45-49 | 0 (NA%) | 19 (1%) | 19 (1%) | |
50-54 | 0 (NA%) | 46 (2%) | 46 (2%) | |
55-59 | 0 (NA%) | 132 (7%) | 132 (7%) | |
60-64 | 0 (NA%) | 280 (14%) | 280 (14%) | |
65-69 | 0 (NA%) | 384 (19%) | 384 (19%) | |
70-74 | 0 (NA%) | 466 (23%) | 466 (23%) | |
> 75 | 0 (NA%) | 681 (34%) | 681 (34%) | |
Unknown | 0 (NA%) | 0 (0%) | 0 (0%) | |
Total | 0 (0%) | 2025 (100%) | 2025 (100%) | |
5.6.3.1.1 Trends over time
5.6.3.2 Distribution of common subsites
5.6.3.2.1 Trends over time
5.6.3.3 Basis of Diagnosis Distribution
5.6.3.3.1 By Gender
5.6.3.3.2 Trends over time
5.6.3.4 Staging Distribution
5.6.3.4.1 Trends over time
5.6.3.5 Types of treatment
5.6.3.5.1 Trends over time
5.6.4 ESOPHAGUS (C15)
5.6.4.1 Age / Gender Distribution
Table X: Name of table | ||||
label | variable | Sex | Total | |
Female | Male | |||
Age Group | 0-4 | 0 (NA%) | 0 (NA%) | 0 (0%) |
5-9 | 0 (NA%) | 0 (NA%) | 0 (0%) | |
10-14 | 0 (NA%) | 0 (NA%) | 0 (0%) | |
15-19 | 0 (NA%) | 0 (NA%) | 0 (0%) | |
20-24 | 9 (50%) | 9 (50%) | 18 (1%) | |
25-29 | 23 (40%) | 34 (60%) | 57 (2%) | |
30-34 | 44 (48%) | 47 (52%) | 91 (3%) | |
35-39 | 38 (32%) | 82 (68%) | 120 (4%) | |
40-44 | 79 (38%) | 127 (62%) | 206 (6%) | |
45-49 | 91 (31%) | 205 (69%) | 296 (9%) | |
50-54 | 112 (31%) | 254 (69%) | 366 (11%) | |
55-59 | 150 (33%) | 303 (67%) | 453 (14%) | |
60-64 | 165 (35%) | 300 (65%) | 465 (14%) | |
65-69 | 176 (43%) | 233 (57%) | 409 (12%) | |
70-74 | 164 (42%) | 224 (58%) | 388 (12%) | |
> 75 | 162 (38%) | 265 (62%) | 427 (13%) | |
Unknown | 0 (NA%) | 0 (NA%) | 0 (0%) | |
Total | 1213 (37%) | 2083 (63%) | 3296 (100%) | |
5.6.4.1.1 Trends over time
5.6.4.2 Distribution of common subsites
5.6.4.2.1 Trends over time
5.6.4.3 Basis of Diagnosis Distribution
5.6.4.3.1 By Gender
5.6.4.3.2 Trends over time
5.6.4.4 Staging Distribution
5.6.4.4.1 Trends over time
5.6.4.5 Types of treatment
5.6.4.5.1 Trends over time
5.6.5 LYMPHOMA (C81-C85, C96)
5.6.5.1 Age / Gender Distribution
Table X: Name of table | ||||
label | variable | Sex | Total | |
Female | Male | |||
Age Group | 0-4 | 95 (37%) | 163 (63%) | 258 (10%) |
5-9 | 143 (34%) | 277 (66%) | 420 (16%) | |
10-14 | 124 (34%) | 237 (66%) | 361 (14%) | |
15-19 | 72 (31%) | 162 (69%) | 234 (9%) | |
20-24 | 66 (50%) | 66 (50%) | 132 (5%) | |
25-29 | 45 (38%) | 74 (62%) | 119 (5%) | |
30-34 | 73 (51%) | 71 (49%) | 144 (6%) | |
35-39 | 72 (53%) | 64 (47%) | 136 (5%) | |
40-44 | 57 (38%) | 94 (62%) | 151 (6%) | |
45-49 | 49 (36%) | 89 (64%) | 138 (5%) | |
50-54 | 42 (40%) | 63 (60%) | 105 (4%) | |
55-59 | 39 (36%) | 68 (64%) | 107 (4%) | |
60-64 | 30 (33%) | 60 (67%) | 90 (3%) | |
65-69 | 27 (44%) | 35 (56%) | 62 (2%) | |
70-74 | 30 (46%) | 35 (54%) | 65 (3%) | |
> 75 | 13 (26%) | 37 (74%) | 50 (2%) | |
Unknown | 1 (100%) | 0 (0%) | 1 (0.04%) | |
Total | 978 (38%) | 1595 (62%) | 2573 (100%) | |
5.6.5.1.1 Trends over time
5.6.5.2 Distribution of common subsites
5.6.5.2.1 Trends over time
5.6.5.3 Basis of Diagnosis Distribution
5.6.5.3.1 By Gender
5.6.5.3.2 Trends over time
5.6.5.4 Staging Distribution
5.6.5.4.1 Trends over time
5.6.5.5 Types of treatment
5.6.5.5.1 Trends over time
5.6.6 Leukemias (C90-C95)
5.6.6.1 Age / Gender Distribution
Table X: Name of table | ||||
label | variable | Sex | Total | |
Female | Male | |||
Age Group | 0-4 | 70 (40%) | 106 (60%) | 176 (6%) |
5-9 | 116 (41%) | 167 (59%) | 283 (9%) | |
10-14 | 108 (40%) | 164 (60%) | 272 (9%) | |
15-19 | 92 (49%) | 94 (51%) | 186 (6%) | |
20-24 | 68 (48%) | 75 (52%) | 143 (5%) | |
25-29 | 70 (48%) | 77 (52%) | 147 (5%) | |
30-34 | 74 (43%) | 100 (57%) | 174 (6%) | |
35-39 | 65 (49%) | 69 (51%) | 134 (4%) | |
40-44 | 65 (40%) | 97 (60%) | 162 (5%) | |
45-49 | 101 (51%) | 96 (49%) | 197 (7%) | |
50-54 | 101 (46%) | 117 (54%) | 218 (7%) | |
55-59 | 110 (49%) | 116 (51%) | 226 (8%) | |
60-64 | 109 (51%) | 105 (49%) | 214 (7%) | |
65-69 | 67 (39%) | 107 (61%) | 174 (6%) | |
70-74 | 64 (43%) | 85 (57%) | 149 (5%) | |
> 75 | 56 (35%) | 102 (65%) | 158 (5%) | |
Unknown | 0 (NA%) | 0 (NA%) | 0 (0%) | |
Total | 1336 (44%) | 1677 (56%) | 3013 (100%) | |
5.6.6.1.1 Trends over time
5.6.6.2 Distribution of common subsites
5.6.6.2.1 Trends over time
5.6.6.3 Basis of Diagnosis Distribution
5.6.6.3.1 By Gender
5.6.6.3.2 Trends over time
5.6.6.4 Staging Distribution
5.6.6.4.1 Trends over time
5.6.6.5 Types of treatment
5.6.6.5.1 Trends over time
5.6.7 TRACHEA, BRONCHUS, LUNG (C33-C34)
5.6.7.1 Age / Gender Distribution
Table X: Name of table | ||||
label | variable | Sex | Total | |
Female | Male | |||
Age Group | 0-4 | 0 (NA%) | 0 (NA%) | 0 (0%) |
5-9 | 1 (100%) | 0 (0%) | 1 (0.2%) | |
10-14 | 0 (0%) | 1 (100%) | 1 (0.2%) | |
15-19 | 1 (33%) | 2 (67%) | 3 (1%) | |
20-24 | 2 (50%) | 2 (50%) | 4 (1%) | |
25-29 | 4 (36%) | 7 (64%) | 11 (2%) | |
30-34 | 11 (58%) | 8 (42%) | 19 (3%) | |
35-39 | 9 (47%) | 10 (53%) | 19 (3%) | |
40-44 | 16 (43%) | 21 (57%) | 37 (6%) | |
45-49 | 22 (54%) | 19 (46%) | 41 (7%) | |
50-54 | 25 (46%) | 29 (54%) | 54 (9%) | |
55-59 | 41 (51%) | 40 (49%) | 81 (14%) | |
60-64 | 31 (42%) | 43 (58%) | 74 (13%) | |
65-69 | 31 (46%) | 37 (54%) | 68 (12%) | |
70-74 | 32 (43%) | 43 (57%) | 75 (13%) | |
> 75 | 30 (49%) | 31 (51%) | 61 (11%) | |
Unknown | 12 (46%) | 14 (54%) | 26 (5%) | |
Total | 268 (47%) | 307 (53%) | 575 (100%) | |
5.6.7.1.1 Trends over time
5.6.7.2 Distribution of common subsites
5.6.7.2.1 Trends over time
5.6.7.3 Basis of Diagnosis Distribution
5.6.7.3.1 By Gender
5.6.7.3.2 Trends over time
5.6.7.4 Staging Distribution
5.6.7.4.1 Trends over time
5.6.7.5 Types of treatment
5.6.7.5.1 Trends over time
5.6.8 KAPOSISARCOMA (C45)
5.6.8.1 Age / Gender Distribution
Table X: Name of table | ||||
label | variable | Sex | Total | |
Female | Male | |||
Age Group | 0-4 | 3 (13%) | 20 (87%) | 23 (1%) |
5-9 | 8 (20%) | 33 (80%) | 41 (2%) | |
10-14 | 15 (38%) | 24 (62%) | 39 (2%) | |
15-19 | 25 (46%) | 29 (54%) | 54 (2%) | |
20-24 | 57 (58%) | 42 (42%) | 99 (4%) | |
25-29 | 139 (48%) | 149 (52%) | 288 (12%) | |
30-34 | 196 (38%) | 317 (62%) | 513 (21%) | |
35-39 | 141 (32%) | 295 (68%) | 436 (18%) | |
40-44 | 126 (35%) | 230 (65%) | 356 (14%) | |
45-49 | 72 (32%) | 156 (68%) | 228 (9%) | |
50-54 | 39 (26%) | 113 (74%) | 152 (6%) | |
55-59 | 24 (27%) | 66 (73%) | 90 (4%) | |
60-64 | 17 (28%) | 44 (72%) | 61 (2%) | |
65-69 | 8 (24%) | 26 (76%) | 34 (1%) | |
70-74 | 9 (24%) | 29 (76%) | 38 (2%) | |
> 75 | 8 (30%) | 19 (70%) | 27 (1%) | |
Unknown | 0 (NA%) | 0 (NA%) | 0 (0%) | |
Total | 887 (36%) | 1592 (64%) | 2479 (100%) | |
5.6.8.1.1 Trends over time
5.6.8.2 Distribution of common subsites
5.6.8.2.1 Trends over time
5.6.8.3 Basis of Diagnosis Distribution
5.6.8.3.1 By Gender
5.6.8.3.2 Trends over time
5.6.8.4 Staging Distribution
5.6.8.4.1 Trends over time
5.6.8.5 Types of treatment
5.6.8.5.1 Trends over time
5.7 Childhood Cancers 0-14 years.
5.7.1 County Distribution Map
5.7.1.1 County Distribution Graph | Top 20 Counties
5.7.1.2 County Distribution Table
Table X: Name of table | ||||
label | variable | Sex | Total | |
Female | Male | |||
County | Baringo | 59 (45%) | 71 (55%) | 130 (3%) |
Bomet | 32 (39%) | 51 (61%) | 83 (2%) | |
Bungoma | 121 (41%) | 172 (59%) | 293 (8%) | |
Busia | 73 (42%) | 100 (58%) | 173 (4%) | |
CENTRAL | 0 (NA%) | 0 (NA%) | 0 (0%) | |
COAST | 0 (NA%) | 0 (NA%) | 0 (0%) | |
EASTERN-NOS | 0 (NA%) | 0 (NA%) | 0 (0%) | |
Elgeyo-Marakwet | 43 (38%) | 69 (62%) | 112 (3%) | |
Embu | 0 (NA%) | 0 (NA%) | 0 (0%) | |
FOREIGN | 0 (0%) | 1 (100%) | 1 (0.03%) | |
Garissa | 0 (NA%) | 0 (NA%) | 0 (0%) | |
Homa-Bay | 29 (35%) | 55 (65%) | 84 (2%) | |
Isiolo | 0 (NA%) | 0 (NA%) | 0 (0%) | |
Kajiado | 0 (0%) | 2 (100%) | 2 (0.05%) | |
Kakamega | 107 (43%) | 141 (57%) | 248 (6%) | |
Kericho | 77 (46%) | 91 (54%) | 168 (4%) | |
Kiambu | 5 (62%) | 3 (38%) | 8 (0.2%) | |
Kilifi | 0 (NA%) | 0 (NA%) | 0 (0%) | |
Kirinyaga | 2 (100%) | 0 (0%) | 2 (0.05%) | |
Kisii | 42 (38%) | 68 (62%) | 110 (3%) | |
Kisumu | 40 (44%) | 51 (56%) | 91 (2%) | |
Kitui | 0 (NA%) | 0 (NA%) | 0 (0%) | |
Kwale | 1 (100%) | 0 (0%) | 1 (0.03%) | |
Laikipia | 2 (33%) | 4 (67%) | 6 (0.2%) | |
Lamu | 0 (NA%) | 0 (NA%) | 0 (0%) | |
Machakos | 1 (50%) | 1 (50%) | 2 (0.05%) | |
Makueni | 0 (0%) | 1 (100%) | 1 (0.03%) | |
Mandera | 0 (0%) | 1 (100%) | 1 (0.03%) | |
Marsabit | 3 (75%) | 1 (25%) | 4 (0.1%) | |
Meru | 2 (100%) | 0 (0%) | 2 (0.05%) | |
Migori | 11 (28%) | 29 (72%) | 40 (1%) | |
Mombasa | 0 (0%) | 4 (100%) | 4 (0.1%) | |
Muranga | 0 (0%) | 2 (100%) | 2 (0.05%) | |
N.EASTERN | 1 (100%) | 0 (0%) | 1 (0.03%) | |
Nairobi | 2 (29%) | 5 (71%) | 7 (0.2%) | |
Nakuru | 37 (38%) | 60 (62%) | 97 (2%) | |
Nandi | 89 (39%) | 141 (61%) | 230 (6%) | |
Narok | 32 (42%) | 45 (58%) | 77 (2%) | |
Nyandarua | 5 (50%) | 5 (50%) | 10 (0.3%) | |
Nyanza | 4 (27%) | 11 (73%) | 15 (0.4%) | |
Nyeri | 1 (50%) | 1 (50%) | 2 (0.05%) | |
Siaya | 20 (38%) | 33 (62%) | 53 (1%) | |
Taita-Taveta | 0 (NA%) | 0 (NA%) | 0 (0%) | |
Tharaka-Nithi | 0 (NA%) | 0 (NA%) | 0 (0%) | |
Trans-nzoia | 82 (42%) | 111 (58%) | 193 (5%) | |
Turkana | 20 (30%) | 46 (70%) | 66 (2%) | |
Uasin-Gishu | 330 (41%) | 482 (59%) | 812 (21%) | |
Unknown | 241 (42%) | 336 (58%) | 577 (15%) | |
Vihiga | 14 (42%) | 19 (58%) | 33 (1%) | |
Wajir | 0 (0%) | 1 (100%) | 1 (0.03%) | |
West Pokot | 57 (40%) | 85 (60%) | 142 (4%) | |
WESTERN | 3 (60%) | 2 (40%) | 5 (0.1%) | |
Total | 1588 (41%) | 2301 (59%) | 3889 (100%) | |
5.7.2 Distribution of Cases by Socio-Demographics
5.7.2.1 Gender
5.7.2.2 Gender + Age Graph
5.7.2.3 Gender + Age Table
Table X: Name of table | ||||
label | variable | Sex | Total | |
Female | Male | |||
Age Group | 0-4 | 578 (44%) | 747 (56%) | 1325 (34%) |
5-9 | 505 (39%) | 785 (61%) | 1290 (33%) | |
10-14 | 505 (40%) | 769 (60%) | 1274 (33%) | |
Total | 1588 (41%) | 2301 (59%) | 3889 (100%) | |
5.7.3 Distribution of Cancer Types
5.7.3.1 Most Common Cancer Types by Gender
5.7.3.2 All Gender
Table X: Frequency and Proportions of all Cancer Types | All Gender | |||||
label | variable | Age Group | Total | ||
0-4 | 5-9 | 10-14 | |||
ICCC | I.a. Lymphoid leukemias | 110 (27%) | 159 (39%) | 136 (34%) | 405 (10%) |
I.b. Acute myeloid leukemias | 25 (16%) | 71 (45%) | 62 (39%) | 158 (4%) | |
I.c. Chronic myeloproliferative diseases | 6 (18%) | 11 (33%) | 16 (48%) | 33 (1%) | |
I.d. Myelodysplastic syndrome and other myeloproliferative diseases | 2 (67%) | 1 (33%) | 0 (0%) | 3 (0.08%) | |
I.e. Unspecified and other specified leukemias | 25 (32%) | 24 (31%) | 28 (36%) | 77 (2%) | |
II.a. Hodgkin lymphomas | 18 (10%) | 61 (32%) | 109 (58%) | 188 (5%) | |
II.b. Non-Hodgkin lymphomas (except Burkitt lymphoma) | 118 (28%) | 172 (41%) | 125 (30%) | 415 (11%) | |
II.c. Burkitt lymphoma | 63 (29%) | 91 (42%) | 64 (29%) | 218 (6%) | |
II.d. Miscellaneous lymphoreticular neoplasms | 1 (100%) | 0 (0%) | 0 (0%) | 1 (0.03%) | |
II.e. Unspecified lymphomas | 19 (30%) | 20 (32%) | 24 (38%) | 63 (2%) | |
III.a. Ependymomas and choroid plexus tumor | 1 (50%) | 1 (50%) | 0 (0%) | 2 (0.05%) | |
III.b. Astrocytomas | 3 (17%) | 5 (28%) | 10 (56%) | 18 (0.5%) | |
III.c. Intracranial and intraspinal embryonal tumors | 6 (24%) | 11 (44%) | 8 (32%) | 25 (1%) | |
III.d. Other gliomas | 6 (30%) | 8 (40%) | 6 (30%) | 20 (1%) | |
III.e. Other specified intracranial and intraspinal neoplasms | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
III.f. Unspecified intracranial and intraspinal neoplasms | 3 (43%) | 1 (14%) | 3 (43%) | 7 (0.2%) | |
IV.a. Neuroblastoma and ganglioneuroblastoma | 35 (56%) | 24 (39%) | 3 (5%) | 62 (2%) | |
IV.b. Other peripheral nervous cell tumors | 0 (0%) | 0 (0%) | 1 (100%) | 1 (0.03%) | |
IX.a. Rhabdomyosarcomas | 86 (50%) | 41 (24%) | 45 (26%) | 172 (4%) | |
IX.b. Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms | 0 (0%) | 6 (67%) | 3 (33%) | 9 (0.2%) | |
IX.c. Kaposi sarcoma | 20 (22%) | 38 (41%) | 35 (38%) | 93 (2%) | |
IX.d. Other specified soft-tissue sarcomas | 11 (32%) | 13 (38%) | 10 (29%) | 34 (1%) | |
IX.e. Unspecified soft-tissue sarcomas | 11 (28%) | 8 (21%) | 20 (51%) | 39 (1%) | |
Other and unspecified | 305 (32%) | 303 (32%) | 335 (36%) | 943 (24%) | |
V. Retinoblastoma | 177 (82%) | 33 (15%) | 5 (2%) | 215 (6%) | |
VI.a. Nephroblastoma and other non:epithelial renal tumors | 222 (65%) | 104 (31%) | 13 (4%) | 339 (9%) | |
VI.b. Wilm’s Tumor | 0 (0%) | 1 (50%) | 1 (50%) | 2 (0.05%) | |
VI.c. Renal carcinomas | 1 (100%) | 0 (0%) | 0 (0%) | 1 (0.03%) | |
VII.a. Hepatoblastoma | 4 (50%) | 2 (25%) | 2 (25%) | 8 (0.2%) | |
VII.b. Hepatic carcinomas | 4 (40%) | 3 (30%) | 3 (30%) | 10 (0.3%) | |
VII.c. Unspecified malignant hepatic tumors | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
VIII.a. Osteosarcomas | 4 (4%) | 21 (21%) | 76 (75%) | 101 (3%) | |
VIII.b. Chondrosarcomas | 1 (50%) | 1 (50%) | 0 (0%) | 2 (0.05%) | |
VIII.c. Ewing’s tumors and related sarcomas of the bone | 0 (0%) | 2 (40%) | 3 (60%) | 5 (0.1%) | |
VIII.d. Other specified malignant bone tumors | 0 (0%) | 1 (33%) | 2 (67%) | 3 (0.08%) | |
VIII.e. Unspecified malignant bone tumors | 1 (25%) | 1 (25%) | 2 (50%) | 4 (0.1%) | |
X.a. Intracranial and intraspinal germ cell tumors | 1 (17%) | 3 (50%) | 2 (33%) | 6 (0.2%) | |
X.b. Malignant extracranial and extragonadal germ cell tumors | 6 (60%) | 1 (10%) | 3 (30%) | 10 (0.3%) | |
X.c. Malignant gonadal germ cell tumors | 4 (21%) | 5 (26%) | 10 (53%) | 19 (0.5%) | |
X.d. Gonadal carcinomas | 0 (0%) | 0 (0%) | 1 (100%) | 1 (0.03%) | |
X.e. Other and unspecified malignant gonadal tumors | 1 (50%) | 1 (50%) | 0 (0%) | 2 (0.05%) | |
XI.a. Other specified malignant tumors | 0 (0%) | 1 (50%) | 1 (50%) | 2 (0.05%) | |
XI.b. Thyroid carcinomas | 0 (0%) | 1 (25%) | 3 (75%) | 4 (0.1%) | |
XI.c. Nasopharyngeal carcinomas | 1 (2%) | 8 (14%) | 49 (84%) | 58 (1%) | |
XI.d. Malignant melanomas | 0 (0%) | 3 (75%) | 1 (25%) | 4 (0.1%) | |
XI.e. Skin carcinomas | 1 (11%) | 3 (33%) | 5 (56%) | 9 (0.2%) | |
XI.f. Other and unspecified carcinomas | 3 (8%) | 11 (30%) | 23 (62%) | 37 (1%) | |
XII.b. Other unspecified malignant tumors | 20 (33%) | 15 (25%) | 26 (43%) | 61 (2%) | |
Total | 1325 (34%) | 1290 (33%) | 1274 (33%) | 3889 (100%) | |
5.7.3.3 Female
Table X: Frequency and Proportions of all Cancer Types | Female | |||||
label | variable | Age Group | Total | ||
0-4 | 5-9 | 10-14 | |||
ICCC | I.a. Lymphoid leukemias | 43 (27%) | 65 (41%) | 51 (32%) | 159 (10%) |
I.b. Acute myeloid leukemias | 17 (24%) | 28 (40%) | 25 (36%) | 70 (4%) | |
I.c. Chronic myeloproliferative diseases | 2 (12%) | 7 (44%) | 7 (44%) | 16 (1%) | |
I.d. Myelodysplastic syndrome and other myeloproliferative diseases | 0 (0%) | 1 (100%) | 0 (0%) | 1 (0.06%) | |
I.e. Unspecified and other specified leukemias | 5 (18%) | 10 (36%) | 13 (46%) | 28 (2%) | |
II.a. Hodgkin lymphomas | 8 (14%) | 15 (26%) | 34 (60%) | 57 (4%) | |
II.b. Non-Hodgkin lymphomas (except Burkitt lymphoma) | 42 (30%) | 55 (39%) | 43 (31%) | 140 (9%) | |
II.c. Burkitt lymphoma | 25 (30%) | 36 (44%) | 21 (26%) | 82 (5%) | |
II.d. Miscellaneous lymphoreticular neoplasms | 1 (100%) | 0 (0%) | 0 (0%) | 1 (0.06%) | |
II.e. Unspecified lymphomas | 7 (30%) | 7 (30%) | 9 (39%) | 23 (1%) | |
III.a. Ependymomas and choroid plexus tumor | 1 (100%) | 0 (0%) | 0 (0%) | 1 (0.06%) | |
III.b. Astrocytomas | 3 (33%) | 2 (22%) | 4 (44%) | 9 (1%) | |
III.c. Intracranial and intraspinal embryonal tumors | 3 (20%) | 7 (47%) | 5 (33%) | 15 (1%) | |
III.d. Other gliomas | 1 (11%) | 4 (44%) | 4 (44%) | 9 (1%) | |
III.e. Other specified intracranial and intraspinal neoplasms | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
III.f. Unspecified intracranial and intraspinal neoplasms | 1 (33%) | 1 (33%) | 1 (33%) | 3 (0.2%) | |
IV.a. Neuroblastoma and ganglioneuroblastoma | 12 (52%) | 9 (39%) | 2 (9%) | 23 (1%) | |
IV.b. Other peripheral nervous cell tumors | 0 (0%) | 0 (0%) | 1 (100%) | 1 (0.06%) | |
IX.a. Rhabdomyosarcomas | 44 (54%) | 18 (22%) | 20 (24%) | 82 (5%) | |
IX.b. Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms | 0 (0%) | 2 (67%) | 1 (33%) | 3 (0.2%) | |
IX.c. Kaposi sarcoma | 1 (4%) | 8 (35%) | 14 (61%) | 23 (1%) | |
IX.d. Other specified soft-tissue sarcomas | 2 (13%) | 8 (53%) | 5 (33%) | 15 (1%) | |
IX.e. Unspecified soft-tissue sarcomas | 3 (20%) | 4 (27%) | 8 (53%) | 15 (1%) | |
Other and unspecified | 141 (36%) | 120 (31%) | 127 (33%) | 388 (24%) | |
V. Retinoblastoma | 91 (86%) | 12 (11%) | 3 (3%) | 106 (7%) | |
VI.a. Nephroblastoma and other non:epithelial renal tumors | 100 (65%) | 50 (32%) | 5 (3%) | 155 (10%) | |
VI.b. Wilm’s Tumor | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
VI.c. Renal carcinomas | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
VII.a. Hepatoblastoma | 1 (50%) | 1 (50%) | 0 (0%) | 2 (0.1%) | |
VII.b. Hepatic carcinomas | 3 (38%) | 3 (38%) | 2 (25%) | 8 (1%) | |
VII.c. Unspecified malignant hepatic tumors | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
VIII.a. Osteosarcomas | 1 (2%) | 8 (17%) | 37 (80%) | 46 (3%) | |
VIII.b. Chondrosarcomas | 1 (50%) | 1 (50%) | 0 (0%) | 2 (0.1%) | |
VIII.c. Ewing’s tumors and related sarcomas of the bone | 0 (0%) | 2 (100%) | 0 (0%) | 2 (0.1%) | |
VIII.d. Other specified malignant bone tumors | 0 (0%) | 0 (0%) | 1 (100%) | 1 (0.06%) | |
VIII.e. Unspecified malignant bone tumors | 0 (0%) | 0 (0%) | 2 (100%) | 2 (0.1%) | |
X.a. Intracranial and intraspinal germ cell tumors | 0 (0%) | 2 (50%) | 2 (50%) | 4 (0.3%) | |
X.b. Malignant extracranial and extragonadal germ cell tumors | 6 (67%) | 0 (0%) | 3 (33%) | 9 (1%) | |
X.c. Malignant gonadal germ cell tumors | 3 (19%) | 3 (19%) | 10 (62%) | 16 (1%) | |
X.d. Gonadal carcinomas | 0 (0%) | 0 (0%) | 1 (100%) | 1 (0.06%) | |
X.e. Other and unspecified malignant gonadal tumors | 0 (0%) | 1 (100%) | 0 (0%) | 1 (0.06%) | |
XI.a. Other specified malignant tumors | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
XI.b. Thyroid carcinomas | 0 (0%) | 1 (33%) | 2 (67%) | 3 (0.2%) | |
XI.c. Nasopharyngeal carcinomas | 1 (7%) | 1 (7%) | 13 (87%) | 15 (1%) | |
XI.d. Malignant melanomas | 0 (0%) | 1 (100%) | 0 (0%) | 1 (0.06%) | |
XI.e. Skin carcinomas | 1 (14%) | 1 (14%) | 5 (71%) | 7 (0.4%) | |
XI.f. Other and unspecified carcinomas | 1 (6%) | 4 (24%) | 12 (71%) | 17 (1%) | |
XII.b. Other unspecified malignant tumors | 7 (27%) | 7 (27%) | 12 (46%) | 26 (2%) | |
Total | 578 (36%) | 505 (32%) | 505 (32%) | 1588 (100%) | |
5.7.3.4 Male
Table X: Frequency and Proportions of all Cancer Types | Male | |||||
label | variable | Age Group | Total | ||
0-4 | 5-9 | 10-14 | |||
ICCC | I.a. Lymphoid leukemias | 67 (27%) | 94 (38%) | 85 (35%) | 246 (11%) |
I.b. Acute myeloid leukemias | 8 (9%) | 43 (49%) | 37 (42%) | 88 (4%) | |
I.c. Chronic myeloproliferative diseases | 4 (24%) | 4 (24%) | 9 (53%) | 17 (1%) | |
I.d. Myelodysplastic syndrome and other myeloproliferative diseases | 2 (100%) | 0 (0%) | 0 (0%) | 2 (0.09%) | |
I.e. Unspecified and other specified leukemias | 20 (41%) | 14 (29%) | 15 (31%) | 49 (2%) | |
II.a. Hodgkin lymphomas | 10 (8%) | 46 (35%) | 75 (57%) | 131 (6%) | |
II.b. Non-Hodgkin lymphomas (except Burkitt lymphoma) | 76 (28%) | 117 (43%) | 82 (30%) | 275 (12%) | |
II.c. Burkitt lymphoma | 38 (28%) | 55 (40%) | 43 (32%) | 136 (6%) | |
II.d. Miscellaneous lymphoreticular neoplasms | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
II.e. Unspecified lymphomas | 12 (30%) | 13 (32%) | 15 (38%) | 40 (2%) | |
III.a. Ependymomas and choroid plexus tumor | 0 (0%) | 1 (100%) | 0 (0%) | 1 (0.04%) | |
III.b. Astrocytomas | 0 (0%) | 3 (33%) | 6 (67%) | 9 (0.4%) | |
III.c. Intracranial and intraspinal embryonal tumors | 3 (30%) | 4 (40%) | 3 (30%) | 10 (0.4%) | |
III.d. Other gliomas | 5 (45%) | 4 (36%) | 2 (18%) | 11 (0.5%) | |
III.e. Other specified intracranial and intraspinal neoplasms | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
III.f. Unspecified intracranial and intraspinal neoplasms | 2 (50%) | 0 (0%) | 2 (50%) | 4 (0.2%) | |
IV.a. Neuroblastoma and ganglioneuroblastoma | 23 (59%) | 15 (38%) | 1 (3%) | 39 (2%) | |
IV.b. Other peripheral nervous cell tumors | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
IX.a. Rhabdomyosarcomas | 42 (47%) | 23 (26%) | 25 (28%) | 90 (4%) | |
IX.b. Fibrosarcomas, peripheral nerve sheath tumors, and other fibrous neoplasms | 0 (0%) | 4 (67%) | 2 (33%) | 6 (0.3%) | |
IX.c. Kaposi sarcoma | 19 (27%) | 30 (43%) | 21 (30%) | 70 (3%) | |
IX.d. Other specified soft-tissue sarcomas | 9 (47%) | 5 (26%) | 5 (26%) | 19 (1%) | |
IX.e. Unspecified soft-tissue sarcomas | 8 (33%) | 4 (17%) | 12 (50%) | 24 (1%) | |
Other and unspecified | 164 (30%) | 183 (33%) | 208 (37%) | 555 (24%) | |
V. Retinoblastoma | 86 (79%) | 21 (19%) | 2 (2%) | 109 (5%) | |
VI.a. Nephroblastoma and other non:epithelial renal tumors | 122 (66%) | 54 (29%) | 8 (4%) | 184 (8%) | |
VI.b. Wilm’s Tumor | 0 (0%) | 1 (50%) | 1 (50%) | 2 (0.09%) | |
VI.c. Renal carcinomas | 1 (100%) | 0 (0%) | 0 (0%) | 1 (0.04%) | |
VII.a. Hepatoblastoma | 3 (50%) | 1 (17%) | 2 (33%) | 6 (0.3%) | |
VII.b. Hepatic carcinomas | 1 (50%) | 0 (0%) | 1 (50%) | 2 (0.09%) | |
VII.c. Unspecified malignant hepatic tumors | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
VIII.a. Osteosarcomas | 3 (5%) | 13 (24%) | 39 (71%) | 55 (2%) | |
VIII.b. Chondrosarcomas | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
VIII.c. Ewing’s tumors and related sarcomas of the bone | 0 (0%) | 0 (0%) | 3 (100%) | 3 (0.1%) | |
VIII.d. Other specified malignant bone tumors | 0 (0%) | 1 (50%) | 1 (50%) | 2 (0.09%) | |
VIII.e. Unspecified malignant bone tumors | 1 (50%) | 1 (50%) | 0 (0%) | 2 (0.09%) | |
X.a. Intracranial and intraspinal germ cell tumors | 1 (50%) | 1 (50%) | 0 (0%) | 2 (0.09%) | |
X.b. Malignant extracranial and extragonadal germ cell tumors | 0 (0%) | 1 (100%) | 0 (0%) | 1 (0.04%) | |
X.c. Malignant gonadal germ cell tumors | 1 (33%) | 2 (67%) | 0 (0%) | 3 (0.1%) | |
X.d. Gonadal carcinomas | 0 (NA%) | 0 (NA%) | 0 (NA%) | 0 (0%) | |
X.e. Other and unspecified malignant gonadal tumors | 1 (100%) | 0 (0%) | 0 (0%) | 1 (0.04%) | |
XI.a. Other specified malignant tumors | 0 (0%) | 1 (50%) | 1 (50%) | 2 (0.09%) | |
XI.b. Thyroid carcinomas | 0 (0%) | 0 (0%) | 1 (100%) | 1 (0.04%) | |
XI.c. Nasopharyngeal carcinomas | 0 (0%) | 7 (16%) | 36 (84%) | 43 (2%) | |
XI.d. Malignant melanomas | 0 (0%) | 2 (67%) | 1 (33%) | 3 (0.1%) | |
XI.e. Skin carcinomas | 0 (0%) | 2 (100%) | 0 (0%) | 2 (0.09%) | |
XI.f. Other and unspecified carcinomas | 2 (10%) | 7 (35%) | 11 (55%) | 20 (1%) | |
XII.b. Other unspecified malignant tumors | 13 (37%) | 8 (23%) | 14 (40%) | 35 (2%) | |
Total | 747 (32%) | 785 (34%) | 769 (33%) | 2301 (100%) | |
5.7.4 Trends of Cancer Incidence over Time
5.7.4.1 All Gender
5.7.4.2 Top 5 in Male
5.7.4.3 Top 5 in Female
6 Results for 2016 to 2021
TODO
7 Results for 2011 to 2015
TODO
8 Results for 2006 to 2010
TODO
9 Results for 2000 to 2005
TODO
10 References
Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, 3rd Edition. Cancer. 2005;103:1457-67.
Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Limited-Use, Nov 2011, 2009 Pops(2000-2009)
- Linked To County Attributes - Total U.S., 1969-2010 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2012, based on the November 2011 submission. Joinpoint Regression Program [computer program]. Version 3.0. Bethesda, MD: National Cancer Institute; April 2005. Available at: http://srab.cancer.gov/joinpoint/. Accessed November 26, 2008.
Howlader N, Ries LA, Mariotto AB, et al. ‘Improved Estimates of Cancer-Specific Survival Rates from Population-Based Data’. Journal of the National Cancer Institute. Vol. 102, Issue 20, p. 1584-1597. October 20, 2010.
American Cancer Society. Childhood Leukemia. Available at: http://www.cancer.org/acs/groups/cid/documents/webcontent/003095-pdf.pdf Accessed April 19, 2013.
Matthew, P, Arceri, R, Smith, F, Grawe, G, Cripe, T, Sakamoto, K, Windle, M. Pediatric Myelodysplastic Sydrome. Medscape Reference. Available at: http://emedicine.medscpae.com/article/988024-overview Accessed April 19, 2013.
American Cancer Society. Non-Hodgkin Lymphoma in Children. Available at: http://www.cancer.org/acs/groups/cid/documents/webcontent/003127-pdf.pdf Accessed April 19, 2013.
Lymphoma Research Foundation. About Lymphoma. Available at: http://www.lymphoma.org/site/pp.asp?c=bkLTKaOQLmK8E&b=6299689 Accessed April 19, 2013.
American Cancer Society. Brain and Spinal Cord Tumors in Children. Available at: http://www.cancer.org/acs/groups/cid/documents/webcontent/003089-pdf.pdf Accessed April 19, 2013.
Kimball’s Biology Pages from Biology by John W. Kimball. Organization of the Nervous System updated on October 21, 2007. Available at: http://users.rcn.com/jkimball.ma.ultranet/ BiologyPages/P/PNS.html Accessed October 2009.
The Biology Corner. Anatomy & Physiology Chapter 5 Histology. Epithelial Tissues [Webpage] Available at: http://www.biologycorner.com/anatomy/histology/index.html. Accessed May 2010.
Massachusetts Cancer Registry. Data Report: Thyroid Cancer in Massachusetts. Boston, MA: Massachusetts Department of Public Health, 2011. Available at http://www.mass.gov/Eeohhs2/docs/dph/cancer/thryod_cancer.pdf. Accessed April 19, 2013.
American Cancer Society. Melanoma Skin Cancer. Available at: http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/index Accessed April 19, 2013.
St. Jude’s Children Research Hospital. Solid Tumor: Rhabdomyosarcoma. Available at: http://www.stjude.org/stjude/v/index.jsp?vgnextoid=64fb061585f70110VgnVCM1000001e0215acRCRD Accessed April 19, 2013.
Dana Farber Cancer Institute. Childhood Fibrosarcoma. Available at: http://www.dana-farber.org/Health-Library/Childhood-Fibrosarcoma.aspx Accessed April 19, 2013.
American Cancer Society, Kaposi Sarcoma. Available at: http://www.cancer.org/acs/groups/cid/documents/webcontent/003106-pdf.pdf Accessed April 23, 2013.
Ross, J, Spector, L. Cancers in Children. In Cancer Epidemiology and Prevention, Schottenfled, D, Fraumeni, J (editors). Oxford University Press USA, August 2006.
Germ Cell Tumors of the Brain. Children’s Hospital. Available at: http://www.childrenshospital.org/az/Site954/mainpageS954P0.html Accessed April 19, 2013.
American Cancer Society. Cancer in Children. Available at: http://www.cancer.org/acs/groups/cid/documents/webcontent/002287-pdf.pdf Accessed April 19, 2013.
American Cancer Society. What is osteosarcoma? Available at: http://www.cancer.org/cancer/osteosarcoma/index Accessed April 19, 2013.
American Cancer Society. Ewing Family of Tumors. Available at: http://www.cancer.org/cancer/ewingfamilyoftumors/detailedguide/index Accessed April 19, 2013.
Kupfer, Gary, Areci, Robert, Gross, Samuel et al. Childhood Cancer Epidemiology. Available at: http://emedicine.medscape.com/article/989841-overview?src=emailthis Accessed March 20, 2014.
National Cancer Institute. Childhood Cancers. Available at: http://www.cancer.gov/cancertopics/factsheet/Sites-Types/childhood/print Accessed February 16, 2011